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Abstract 
Zimmermann-Laband syndrome (ZLS; MIM135500) is a rare developmental disorder 
characterized by facial dysmorphism, including coarsening of the face, bulbous soft nose, gingival 
enlargement, nail aplasia or hypoplasia, hypertrichosis, and intellectual disability, with or without 
epilepsy. To date, about 40 patients have been described with features fitting ZLS.   
With the aim of identifying ZLS causative gene/s a WES approach on three ZLS patients 
was performed and allowed us to identify two disease genes, KCNH1 and ATP6V1B2 (Kortum et 
al., 2015). An enlargement of the cohort was performed through the recruitment of further five 
patients, that were analyzed by WES or Sanger sequencing, disclosing the presence of additional 
mutations in KCNH1 and ATP6V1B2 genes (Kortum et al., 2015), and highlighting the role of 
potassium channels and vacuolar ATPase in the pathogenesis of this disease. 
KCNH1 gene encodes a member of the potassium channel, voltage-gated, subfamily H 
protein. Patch-clamp recordings on KCNH1 mutants identified in this work showed strong negative 
shifts in voltage-dependent activation, supporting a possible gain-of-function effect for all ZLS-
associated KCNH1 mutants.  
ATP6V1B2 gene encodes the B2 subunit of the multimeric vacuolar H+ ATPase. Structural 
analysis predicts a perturbing effect of the mutation on complex assembly. 
Sanger sequencing screening of the coding sequence of the KCNH1 and ATP6V1B2 genes in 
four patients with clinical features within the ZLS clinical spectrum, disclosed the presence of 
mutation-negative patients, pointing to genetic heterogeneity for ZLS. To identify the “missing” 
ZLS disease genes, a WES approach on two KCNH1 and ATP6V1B2 mutation-negative subjects 
was performed, disclosing the presence of a novel likely pathogenic de novo variant in ATP6V1C1, 
encoding an interactor of ATP6V1B2. 
Common clinical features of patients mutated in KCNH1, ATP6V1B2 and ATP6V1C1 genes 
include craniofacial dysmorphism, gingival enlargement, mild to severe intellectual disability, and 
aplastic or hypoplastic nails and terminal phalanges, although with remarkable variability. Epilepsy 
is present only in KCNH1 mutated patients.  
A recruitment of additional ZLS and ZLS-related patients is ongoing; these subjects will be 
screened for mutations in previously and newly identified disease genes in order to provide a more 
accurate picture of the molecular spectrum of mutations and their associated clinical spectrum.  
Structural and functional studies are ongoing to characterize the effect of the ATP6V1B2 
and ATP6V1C1 mutants on the proper assembly/activity of the ATPase complex. 
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1. Introduction 
1.1 Zimmermann-Laband Syndrome: review of the literature 
Zimmermann-Laband syndrome (ZLS; MIM135500), firstly described by Zimmermann 
(1928) in two patients, is a rare developmental disorder characterized by facial dysmorphism, such 
as coarsening of the face, bulbous soft nose, gingival enlargement and thick floppy ears, nail aplasia 
or hypoplasia, hypertrichosis, and intellectual disability, with or without epilepsy (Balasubramanian 
and Parker, 2010). Although, Zimmermann is considered the first describing this condition, a 
patient with similar features has been reported in 1886 by Humphry, which presented a patient with 
only the left side of the body affected. She showed gingival hyperplasia, long eyelashes and 
eyebrows, thick floppy ear, facial hypertrichosis, hypoplasia of nail and terminal phalange of the 
second digit of the foot  (figure 1). 
 
 
Figure 1. Original drawing of the patient described by Humphry (1886). Unilateral gingival hyperplasia can be 
observed. 
 
Laband (1964) and Alavandar (1965) reported two Asiatic Indian families in which gingival 
fibromatosis occurred in association with hypoplasia of the terminal phalanges and absence or 
dysplasia of the fingernails. The report by Laband (1964) described the disorder in an East Indian 
38-year-old woman and 5 of her 7 children. The mother showed large, soft ears, hypertension, 
hyperextensibility of metacarpophalangeal joints, and splenomegaly. The affected children had soft 
tissue enlargement of the nose and ears, splenomegaly, skeletal abnormalities, reduced size of 
toenails and thumbnails, short terminal phalanges, and hypermobility of several joints. The report 
by Alavandar (1965) described 5 affected persons in 3 generations with associated features of 
thickening of the soft tissues of the nose and ear with softness of the cartilages, hyperextensible 
joints, and hepatomegaly. 
Chodirker et al. (1986) reported a case of a syndrome that he named for the first time 
Zimmermann-Laband, characterized by profound mental retardation, gingival fibromatosis, and 
absence of nails of thumbs and halluces.  
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Pina-Neto et al. (1988) reported a female patient with bulbous soft nose, thick floppy ears, 
gingival hypertrophy, large tongue, generalized hypertrichosis, joint laxity, hepatosplenomegaly, 
hypoplasia of distal phalanges of thumbs, thumbnails and toenails, generalized hypotonia, delayed 
neuromotor and speech development, mild mental retardation, lordosis, and flat feet. 
Bakaeen and Scully (1991) described two siblings with Zimmermann-Laband syndrome, 
characterized by a pronounced gingival hyperplasia, thickened and enlarged ears and nose, nail 
dysplasia, hypoplastic terminal phalanges, hyperextensibility of the joints, and hepatosplenomegaly. 
In 1992, Pfeiffer et al. described two patients with gingival fibromatosis, swelling of 
perioral tissues, nail hypo/aplasia, and abnormalities of terminal phalanges. 1 of the two patients 
suffers from epileptic seizures and shows osseous mandibular hypertrophy, two maxillary 
mesiodentes and lumbar spondylodysplasia. In the same year, Koch and collaborators reported on a 
10-year-old girl with a diagnosis of Zimmermann-Laband syndrome, associated with an atypical 
retinitis pigmentosa.  
Van Buggenhout et al. (1995) reported a 54 year-old male patient with Zimmermann-
Laband syndrome, showing severe mental retardation, gingival hyperplasia, bulbous soft nose, thick 
floppy ears, full eyebrows, nails aplasia, hypoplastic distal phalanges with abnormal shape of the 
thumb phalanges of hands and feet, and scoliosis. 
Robertson et al. (1998) reported on a 4-decade follow-up of a male with Zimmermann-
Laband syndrome who developed a cardiomyopathy and dilatation of the aortic root and arch. 
Dumic et al. (1999) reported a Croatian son of non consanguineous parents that had gingival 
hyperplasia and overgrowth of the major portion of the palatal tissue, bulbous soft nose and ears, 
hypoplastic toenails, hyperextensibility of the metacarpophalangeal joints, deep palmar and plantar 
crease, large tongue, and hypoplastic toenails. 
In the report of a balanced reciprocal translocation in mother and daughter by Stefanova et 
al. (2003), the 40-year-old proposita had been referred to the dental clinic at age 16 years because 
of excessive gingival growth that completely covered the tooth crowns. She and her daughter, 
showed gingival hyperplasia, large fleshy nose, macrostomia, full lips, large tongue, large thick 
eyelashes, and normal intelligence. The mother showed dystrophic fingernails and aplasia of the 
toenails, whereas the daughter had aplasia of both the fingernails and toenails, prominent ears, and 
generalized hirsutism. 
Shah and coworkers (2004) presented an unusual case of Zimmermann-Laband syndrome in 
a young male with bilateral developmental cataract. 
In 2005, Holzhausen and collaborators published a report describing a 13-year-old female 
patient with previously undiagnosed Zimmermann-Laband syndrome, having the following clinical 
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and radiographic alterations: thick floppy ears, bulbous soft nose, prominent maxillae, thick lips, 
thick eyelashes and eyebrows, mild hirsutism, hypertelorism, telecanthus, short neck, high foot 
arch, hypoplasia of toenails, deformed terminal phalanges of the toes and thumbs, and 
hyperextensibility of the metacarpophalangeal joints, and supernumerary teeth. The patient did not 
have intellectual disability. 
Davalos et al. (2005) reported two unrelated children, a boy and a girl, clinically and 
radiologically diagnosed with ZLS who displayed previously unreported features, such as: marked 
body overgrowth, cavernous hemangiomata in the frontal and left cerebellar regions in the boy, and 
unusual radiologic characteristics including broad medullary canals and metaphyses of the long 
bones, thin cortices, broad ribs, and accelerated skeletal maturation in the girl. The boy had 
psychomotor delay, whereas the girl had normal intelligence. The girl's mother and two brothers 
had also mild hypertrichosis but no other features of ZLS. The boy's father had soft tissue 
enlargement of the nose, ears, and lips. 
A further 4-months-old male subject with ZLS was reported by Atabek et al. in 2005. He 
was the first child of a young non consanguineous couple. The upper part of his mouth showed a 
hyperplastic gingiva, and, in addition, he had a markedly generalized hypertrichosis, dysplastic nails 
of the fingers and toes, hyperpigmented scrotal skin, hyperextensible metacarpophalangeal joints, 
and deep palmar and plantar creases. 
Hoogendijk and coworkers reported in 2006 a 14-year-old child with a gross hypertrophy of 
the maxillary and mandibular gingiva. His facial features include a bulbous soft nose, thick upper 
and lower lips, a low anterior hairline, and bushy eyebrows. Abnormalities of the nails of the feet 
were noted. 
In the work of Kim et al. (2007), a male 46,XY,t(3;17)(p14.3;q24.3) with gingival 
hyperplasia, hypertrichosis, unusually large ears and marked hypertrophy of the nose is presented. 
Abo-Dalo (2007 and 2008) reported three novel patients with ZLS. They shared as main 
clinical features hypoplastic terminal phalanges, aplastic nails, gingival fibromatosis, and mental 
retardation. One of them had macrocephaly and behavioral problems, another one had bulbous flat 
nose, macroglossia, hypertrichosis, while the third one had seizures, microcephaly, short stature, 
and scoliosis. Those three subjects were analyzed in the present research project, and correspond to 
case 5, 6 and 8, respectively. 
Lin et al. described a patient with ZLS diagnosis in 2010. The diagnosis was made on the 
presence of gingival fibromatosis, bulbous nose, thick lips, hirsutism, deformed terminal phalanges, 
splenomegaly, and mental retardation. The patient exhibited also supernumerary teeth and thymic 
hyperplasia. 
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Chacon-Camacho and collaborators (2011) expanded the phenotypic spectrum of ZLS, 
reporting a patient with colpocephaly, hemivertebra, polydactyly, hyperpigmentation, and 
hemihyperplasia. 
Davalos et al. (2011) reported a 9-year-old girl with Zimmermann-Laband syndrome. The 
patient had macrosomia, macrocephaly, generalized hypertrichosis, hepatomegaly, nail hypoplasia, 
gingival hyperplasia, and facial dysmorphism. She had severe bilateral sensorineural hearing loss. 
An additional patient was reported by Sawaki et al. (2012) having the classical features of ZLS. 
Castori et al. (2013) described two unrelated subjects with Zimmermann-Laband syndrome 
who were analyzed in the current study (corresponding to case 1 and 2 in this work). One patient, 
was the unique son of unrelated parents. He had mild generalized hypertrichosis, anonychia of the 
thumbs and great toes, hypoplasia of nails of the fifth fingers and fourth left finger, gingival 
hypertrophy, soft nose, his psychomotor development was delayed with severe motor impairment, 
and seizures. The second patient, was a 5-year-old girl. She was the only child of two non 
consanguineous parents. At birth, she had generalized hypotonia, coarse face, hirsutism, and nails 
hypoplasia of hands and feet, aplasia or hypoplasia of phalanges on both hands and feet, delayed 
psychomotor development, gingival hypertrophy, soft nose and ear cartilages, and hirsutism. Figure 
2 illustrates some pictures representing the most typical features of Zimmermann-Laband 
syndrome. 
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Figure 2. Main ZLS features. (A-G) Typical facial appearance of ZLS patients, with flat nasal bridge, bulbous nose, 
thick ears, in D gingival hyperplasia can be observed; (H-L) Picture showing gingival hyperplasia; (M-R) pictures 
showing aplasia/hypoplasia of nails and terminal phalanges of hands, in M, N, and O the aplasia of nails and hypoplasia 
of terminal phalanges is evident, in P, Q and R hypoplasia of nails; (S-X) pictures showing aplasia of feet nails, in S and 
X can also be noted hypertrichosis; (Y,Z) two pictures showing an example of back and limb hirsutism. 
(A and H, Laband et al., 1964; B, I, M and S, Stefanova et al., 2003; C and N, Abo-Dalo et al., 2008; D, 
Balasubramanian and Parker, 2010; E and J, Davalos et al., 2011; F, K, O, P, T and U, Castori et al., 2013; L, Q, R, V-
X, Kortum et al., 2015; Y and Z, Kim et al., 2007) 
 
1.2 Clinical features of Zimmermann-Laband syndrome 
All the patients reported in literature with the diagnosis of ZLS share some clinical features, 
such as gingival hyperplasia, hypoplasia or aplasia of nails and phalanges. Most of them have 
bulbous soft nose and thick lips, and in different proportion: soft dysmorphic ears (40%), joint 
hypermobility (48%), generalized hypertrichosis (37%), intellectual disability (40%), and epilepsy 
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(14%). Other less frequent characteristics are: thick eyebrows and long eyelashes (27%), 
hypertelorism (12%), downslanting palpebral fissures (10%), micrognathia (27%), high-arched or 
cleft palate (21%), supranumerary teeth or hypodontia (12%), macroglossia (23%), joint 
contractures (4%), hypotonia (12%), pes planus or cavus (10%), hallux valgus (8%), short neck 
(10%), spine anomalies (15%), undertubulated long bones (4%), growth delay or short stature (8%), 
hemihyperplasia or body overgrowth (4%), soft skin (12%), hyperpigmentation (4%), deep palmar 
or plantar creases (4%), cataract (6%), deafness (4%), hepatomegaly (27%), splenomegaly (17%), 
heart defects (12%), and abnormal genitalia (6%) (Castori et al., 2013). Most of the symptoms 
manifest during infancy. In table 1 a list of the main features of ZLS as reported in the clinical 
synopsis of OMIM is reported. An autosomal dominant inheritance with de novo mutations is the 
proposed mode of inheritance for this disease, even though autosomal recessive inheritance could 
not be excluded. X-linked inheritance was less likely because there is no reported imbalance 
between the two sexes. 
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ZIMMERMANN-LABAND SYNDROME FEATURES (MIM135500) 
TYPE OF ANOMALIES DESCRIPTION 
Weight Weight at birth >90th centile 
Facial dysmorphism 
Coarse facies 
Prominent mandible 
Broad nasal bridge 
Fleshy nose 
Thick lips 
Gingival fibromatosis/hyperplasia 
High-arched palate 
Long, lobulated, posteriorly rotated ears 
Hair anomalies 
Thick eyebrows 
Synophrys 
Hypertrichosis 
Hearing anomalies Hearing loss (rare) 
Vision anomalies Myopia Cataracts 
Teeth anomalies Delayed tooth eruption 
Cardiovascular anomalies 
Cardiomyopathy 
Patent ductus arteriosus 
Aortic root/arch dilatation 
Liver/Spleen/Kidneys anomalies 
Hepatosplenomegaly 
Extrahepatic biliary atresia (rare) 
Renal calculi (rare) 
Spine anomalies Scoliosis Spina bifida occulta 
Hands and feet anomalies 
Hyperextensible fingers 
Hypoplastic distal phalanges 
Hypoplastic nails 
Skin anomalies Dry, thick skin 
Neurological anomalies 
Hypotonia 
Seizures 
Intellectual disability 
 
Table 1. Main clinical features of Zimmerman-Laband syndrome as reported in clinical synopsis of OMIM. 
 
1.3 Zimmermann-Laband-related syndromes 
ZLS belongs to a group of syndromes characterized by considerable clinical overlap, such as 
autosomal recessive deafness, onychodystrophy, osteodystrophy, mental retardation, seizures 
syndrome (DOORS; MIM220500), Cantu syndrome (CS; MIM239850), Temple-Baraitser 
syndrome (TMBTS; MIM611816), and dominant deafness-onychodystrophy syndrome (DDOD; 
MIM124480). 
Overlapping characteristics among those syndromes are coarse facies, absence or hypoplasia 
of phalanges and nails, seizures, intellectual disability, and hypertrichosis. There are also some 
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clinical differences, e.g. the autosomal recessive deafness, onychodystrophy, osteodystrophy, 
mental retardation, seizures syndrome (DOORS) has a more severe phenotype involving the central 
nervous system, vision anomalies (blindness, optic atrophy or cataract), profound sensorineural 
deafness, cerebral atrophy with enlarged ventricles, and peripheral polyneuropathy. 
In Cantu syndrome (CS), cardiovascular malformations like cardiomegaly, congenital 
hypertrophy of left ventricle, bicuspid aortic valve, and patent ductus arteriosus are much more 
frequent. In addition, skeletal abnormalities as widened ribs, osteoporosis, platyspondily, and 
widened metaphyses are more frequently observed. 
The dominant deafness-onychodystrophy syndrome (DDOD) differs from ZLS mainly for 
the constant presence of sensorineural hearing loss. Finally, Temple-Baraitser syndrome (TMBTS) 
is characterized by a more severe central nervous system involvement than ZLS, with delayed 
psychomotor development, seizures, intellectual disability, and hypotonia. In ZLS, those neurologic 
findings are not always present, and can have very different degrees of severity, from mild to very 
severe. A comparison among ZLS and the above cited syndromes is presented in table 2. 
 
CLINICAL FEATURES ZLS TMBTS CS DOORS DDOD 
Overgrowth at birth  + - + - - 
Coarse facies   + - + + - 
Hearing loss + - - - + 
Myopia and/or cataracts + - - + - 
Broad nasal bridge     + + + + - 
Fleshy nose  + - - - - 
Thick lips   + + + + - 
Gingival fibromatosis and/or hyperplasia + - + - - 
Aortic root and/or arch dilatation    + - - - - 
Hepatosplenomegaly      + - - - - 
Scoliosis    + - - - - 
Joint hypermobility + - - - - 
Hypoplastic nails and/or distal phalanges + + - + + 
Hypertrichosis     + - + - - 
Hypotonia    + + - + - 
Seizures      + + - + - 
Intellectual disability + + + + - 
 
Table 2. Major clinical features of ZLS, compared with four related syndromes. + = present; - = absent; ZLS = 
Zimmermann-Laband syndrome; CS = Cantu Syndrome; DOORS = deafness, onychodystrophy, osteodystrophy, 
mental retardation, seizures syndrome; DDOD = dominant deafness-onychodystrophy syndrome. 
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1.4 Molecular bases of ZLS-related syndromes 
Mutated genes causative of ZLS-related syndromes have been identified in the last five 
years, using next generation sequencing approach, mainly whole-exome sequencing. 
The first ZLS-related syndrome for which the molecular bases were characterized is the 
Cantu syndrome, caused by de novo mutations in the ABCC9 gene (Harakalova et al., 2012; van 
Bon et al., 2012). The protein encoded by this gene is a member of the superfamily of ATP-binding 
cassette (ABC) transporters. ABCC9 is a member of the MRP subfamily which is involved in 
multi-drug resistance, and is thought to form ATP-sensitive potassium channels in cardiac, skeletal, 
and vascular and non-vascular smooth muscle. 
Afterwards, mutations in the TBC1D24 gene, encoding a protein with a TBC domain, were 
found to be causative of the DOORS syndrome (Campeau et al., 2014; Azaiez et al., 2014). TBC 
domain containing proteins may serve as specific GTPase-activating proteins, the Rab (Ras-related 
proteins in brain) small GTPases which are involved in the regulation of membrane trafficking. This 
protein is apparently not functionally linked to the ABCC9 protein.  
Lately, the DDOD syndrome was found to be caused by a de novo truncating mutation in the 
ATP6V1B2 gene (Yuan et al., 2014), encoding a component of vacuolar ATPase (V-ATPase), a 
multisubunit enzyme that mediates acidification of eukaryotic intracellular organelles. V-ATPase 
dependent organelle acidification is necessary for protein sorting, zymogen activation, receptor-
mediated endocytosis, and synaptic vesicle proton gradient generation. ATP6V1B2 is highly 
expressed in osteoclasts. 
Finally, Simons and coworkers (2015) found that TMBTS is caused by mutations in 
KCNH1. This gene encodes a pore-forming (alpha) subunit of a voltage-gated non-inactivating 
delayed rectifier potassium channel, subfamily H. It is activated at the onset of myoblast 
differentiation, and is highly expressed in brain. Since ABCC9 and KCNH1 encode proteins that 
constitute potassium channels, TMBTS and CS appear to be determined by a dysregulation of the 
intracellular potassium omeostasis. 
 
1.5 Aim of the work 
The aim of this project was the identification of genes underlying Zimmermann-Laband 
syndrome. To this aim, we selected a panel of clinically well-characterized ZLS patients, to be 
analyzed through a Whole-Exome Sequencing approach (WES). Our understanding of the 
molecular events underlying this condition could provide new tools for diagnosis of this rare 
disorder, with direct impact on diagnosis, prognosis, counseling, and patient management. 
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2. Materials and methods 
2.1 Subjects 
In this study, we selected, in the first step of the work, 3 subjects with a phenotype fitting the 
ZLS clinical features. They were clinically assessed by clinical geneticists and neurologists, from 
the Department of Pediatrics and Infantile Neuropsychiatry, “Sapienza” University of Rome, 
Department of Molecular Medicine, “Sapienza” University of Rome - San Camillo-Forlanini 
Hospital (Rome), Bambino Gesù Children’s Hospital (Rome), respectively. Case 1 and 2 were 
previously reported by Castori et al., 2013.  
After the first step of recruitment and analysis, 5 further patients were added to the cohort, 
thanks to an international collaboration with the following centres: University of Hamburg 
(Germany), Zentrum für Kinder-und Jugendmedizin of Oldenburg (Germany), Sydney Children’s 
Hospital (Australia), University of New South Wales (Australia), Saveetha Medical College and 
Hospital (India), University of Montreal (Canada), Centre Hospitalier de la Haute-Saône (France), 
Royal Children’s Hospital and University of Melbourne (Australia), University of Montreal 
(Canada). 
In a third step, 4 further patients were enrolled in the study, from the Università Cattolica del 
Sacro Cuore (Rome), Bambino Gesù Children’s Hospital (Rome), Federico II University (Naples), 
and Azienda Ospedaliero - Universitaria “Meyer” (Florence). 
Informed consent for DNA storage and genetic analyses was obtained from the parents or 
legal guardians of all subjects. Genetic studies were approved by all the institutional review boards 
of the participating institutions. Permission to publish photographs was given for all subjects shown 
in this work. 
 
2.2 Sequencing approach 
In the first 3 selected subjects (case 1, 2 and 3), we used a Whole-Exome Sequencing 
approach (WES). In case 2 and 3 we sequenced the trio, in case 1 only the proband. In a second 
phase of this study the ZLS cohort was expanded with 5 further patients. In two of them (case 4 and 
8, and the relative parents) a WES approach was performed, while, in the other three subjects (case 
5, 6, and 7) a Sanger sequencing of the coding portion of the newly identified genes was used. 
Validations of candidate variants of cases 4 and 8, and Sanger screening of cases 5-7 was performed 
by researchers from the University of Hamburg (Germany). Finally, the more recently selected 
patients (cases 9-12) were firstly analyzed by Sanger sequencing of the coding portion of the newly 
identified genes (KCNH1 and ATP6V1B2), and then two patients (cases 9 and 10) were analyzed 
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through WES of the probands and their parents. WES data analysis of case 10 is still ongoing (table 
3). 
 
Case Sequencing approach Trio/Singleton Enrichment kit NGS platform 
1 WES Singleton NimbleGen SeqCap EZ v3.0 (Roche) 
HiSeq 2000 
(Illumina) 
2 WES Trio NimbleGen SeqCap EZ v3.0 (Roche) 
HiSeq 2000 
(Illumina) 
3 WES Trio SureSelect AllExonV4 (Agilent) 
HiSeq 2000 
(Illumina) 
4 WES Trio TruSeq Exome Enrichment kit (Illumina) 
HiSeq 2000 
(Illumina) 
5 Sanger / / / 
6 Sanger / / / 
7 Sanger / / / 
8 WES Trio TruSeq Exome Enrichment kit (Illumina) 
HiSeq 2000 
(Illumina) 
9 WES Trio SureSelect Clinical Research Exome kit (Agilent) 
NextSeq500 
(Illumina) 
10 WES Trio SureSelect Clinical Research Exome kit (Agilent) 
NextSeq500 
(Illumina) 
11 Sanger / / / 
12 Sanger / / / 
 
Table 3. Schematic representation of the sequencing approach performed on our cohort. WES = Whole-Exome 
Sequencing. 
 
2.3 Whole-exome sequencing of ZLS selected patients 
Targeted enrichment and massively parallel sequencing were performed on genomic DNA 
of seven cases and the parents of six of them (cases 2, 3, 4, 8, 9, and 10). The DNA was extracted 
from circulating leukocytes using the Gentra Puregene Blood Kit (Qiagen). Enrichment of the 
whole-exome was performed using the NimbleGen SeqCap EZ Library v.3.0 (64 Mb) (Roche) for 
cases 1 and 2 (and her parents), the SureSelect AllExonV4 (51 M) (Agilent) for case 3 and her 
parents, the TruSeq Exome Enrichment kit (Illumina) for cases 4 and 8 and their respective parents, 
and the SureSelect Clinical Research Exome kit for case 9 and her parents. Each captured library 
was then loaded onto the HiSeq 2000 platform (Illumina) for cases from 1 to 8 and onto the 
NextSeq500 platform (Illumina) for cases 9 and 10. Raw image files were processed for base 
calling by the on-instrument software.  
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2.4 Whole-exome sequencing: data analysis and variant/gene annotation 
Reads were aligned to the human reference genome (UCSC GRCh37/hg19) using the 
Burrows-Wheeler Aligner v.0.7.10 (Li and Durbin, 2009). PCR duplicates were removed using 
Picard's MarkDuplicates. 
Single Nucleotide Variants (SNVs) and small indels were identified by means of the GATK 
HaplotypeCaller and UnifiedGenotyper algorithms (McKenna et al., 2010): the former calls SNVs 
and indels simultaneously via local de novo assembly of haplotypes. Whenever the program 
encounters a region showing signs of variation, it discards the existing mapping information and 
completely reassembles the reads in that region. This allows the HaplotypeCaller to be more 
accurate for difficult regions, for example containing variants mapping close to each other. 
HaplotypeCaller identifies more accurately indels than UnifiedGenotyper. The latter uses a 
Bayesian genotype likelihood model to estimate simultaneously the most likely genotypes. The 
called variants were filtered applying the following quality filters: variants with quality >100, and 
quality-by-depth score >1.5 (the quality parameter normalized by the number of the reads) were 
retained; variants below these thresholds or resulting from four or more reads having ambiguous 
mapping (this number being greater than 10% of all aligned reads) were discarded. Only variants 
called by both algorithms were considered. 
Since the disease is very rare it could be hypothesized that the causative mutation is not 
present or is annotated with a very low frequency in databases containing data of the DNA variants 
of the population. Therefore, variants were annotated using frequency data obtained from publicly 
available databases (dbSNP138 for cases 1-8 and dbSNP142 for cases 9 and 10, and ExAC) and an 
in-house database.  
 dbSNP is the acronym of Single Nucleotide Polymorphism database 
(https://www.ncbi.nlm.nih.gov/snp), a public-domain archive for a broad collection of simple 
genetic polymorphisms. This collection of polymorphisms includes single-base nucleotide 
substitutions, small deletions or insertions, retroposable element insertions and microsatellite repeat 
variations. ExAC (Exome Aggregation Consortium) (http://exac.broadinstitute.org/) contains DNA 
variants obtained from 60706 unrelated individuals sequenced as part of disease-specific and 
population genetic studies (Lek et al., 2016). Finally, the in-house database is composed of variants 
identified through WES approach in subjects affected by different developmental diseases, and their 
parents studied in our research group and collaborating groups. This database represented a useful 
tool to filter variants that represent high frequency polymorphisms and recurrent artifacts due to 
sequencing technology. 
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We set as a Minor Allele Frequency (MAF) threshold  0.1%, and retained only not annotated 
variants, variants of unknown frequency, and variants with MAF <0.1%. We retained also clinically 
associated variants according to ClinVar database. ClinVar is a freely accessible, public archive of 
reports of the relationships among human variations and phenotypes, with supporting evidence. 
 To predict the functional impact of variants, we used SnpEff toolbox v.3.6 (Cingolani et 
al., 2013), an annotation tool that provides information at variant level: the effect of the variant on 
the transcript, the changed codon, and the isoform used to annotate the variant (usually the isoform 
for which the variant effect is greater or the longest isoform if the effect is the same).  
 Since the phenotype is very severe, it is likely that the causative variant(s) has(have) a 
great impact on the function of the protein or in the maturation of the transcript. We therefore 
retained only functionally relevant variants (i.e., missense, nonsense and coding indel variants and 
intronic variants located from −5 to +5 with respect to an exon-intron junction). 
 Further functional annotations regarding either the variant or the gene were added using 
SnpEff v.3.6 and dbNSFP v.2.5 (Cingolani et al., 2013). Several scores were used to evaluate the 
functional impact of the variant on the function of the protein, e.g. Polyphen-2, SIFT, and CADD. 
Polyphen-2 predicts possible impact of an amino acid substitution on the structure and function of a 
human protein. This prediction is based on a number of features including the sequence, and 
phylogenetic and structural information related to the substitution. The substitution can be classified 
as “probably damaging”, “possibly damaging”, “benign” and “unknown”, if the lack of data does 
not allow to perform a prediction (Adzhubei et al., 2010).  SIFT (Sorting Tolerant From Intolerant) 
assesses the effect of a substitution assuming that crucial positions in protein sequences have been 
conserved throughout evolution and therefore substitutions at these positions may affect protein 
function. By using sequence homology, SIFT predicts the effects of all possible substitutions at 
each position in the protein sequence, with a score ranging from 0 to 1. The amino acid substitution 
is predicted as “damaging” if the score is <= 0.05, and “tolerated” if the score is > 0.05 (Kumar et 
al., 2009). Combined Annotation-Dependent Depletion (CADD) is a tool for scoring the 
deleteriousness of single nucleotide variants as well as insertion/deletions variants in the human 
genome, integrating multiple annotations into one metric by comparing variants that survived 
natural selection with simulated mutations (Kircher et al., 2014). It ranges from 0 to, theoretically, 
infinite, with a threshold of 15 usually used to consider a variant potentially pathogenetic. 
 Information regarding genes was retrieved from several databases such as: OMIM (Online 
Mendelian Inheritance in Man), a database that collects information about human mendelian 
diseases and/or phenotype and associated genes (https://omim.org/), Uniprot (Universal Protein 
Resource), a comprehensive resource for protein sequence and annotation data, used to obtain 
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information regarding the pathway in which the gene is involved (http://www.uniprot.org/), and 
GeneOntology (GO), a project that collects biological functions of genes at the molecular, cellular 
and tissue system levels (http://geneontology.org/). 
 
2.5 Selection of candidate variants 
After the steps of filtering and annotation of variants and genes, we selected the candidate 
variants using different criteria: segregation, effect of the variant, function of the gene, and 
involvement in a known disease. 
Regarding the segregation, we considered different mode of inheritance: autosomal 
dominant, autosomal recessive, and X-linked. When possible, i.e. when the trio was sequenced, also 
the de novo variants were considered. 
The variants were also prioritized considering the conservation of the amino acidic residue, 
pathogenicity/deleteriousness of the variant, and information about the function of the genes and 
their involvement in a known disease. As the three patients had the same clinical diagnosis, we 
looked at first for the presence of the same putative causative variant or different variants in the 
same gene in at least two patients. 
 
2.6 Variant validation and mutation analysis 
Candidate variants validation, segregation analyses, and Sanger screening were performed 
by PCR (GoTaq Flexi DNA Polymerase – Promega) followed by Sanger sequencing. Primers were 
designed in intronic regions flanking the coding exons of KCNH1 (NC_000001.11, 210678315–
211134115, complement), ATP6V1B2 (NC_000008.11, 20197193-20221696), and ATP6V1C1 
(NC_000008.11, 103021020-103073057) in order to have the same annealing temperature. The 
amplification was performed using the following temperature cycle: initial denaturation at 95°C for 
2’, then the next three steps were repeated for 30 times, denaturation at 95°C for 30’’, annealing at 
60°C for 30’’, elongation at 72°C for 30’’, then final elongation at 72°C for 5’, and finally the 
reaction was terminated at 4°C for 5’. Amplicons were directly sequenced using the ABI BigDye 
Terminator Sequencing kit (Life Technologies) and an automated capillary sequencer (ABI3500, 
Life Technologies). Sequence electropherograms were analyzed using Sequencing Analysis 
Software v.5.4 (Life Technologies). Genotyping was carried out with the AmpFlSTR Identifiler 
Plus (Life Technologies) to confirm paternity and maternity. The sequence of the primers used for 
amplification and sequencing are listed in the following tables (tables 4 and 5). 
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Gene Name Sequence (5’->3’) Gene Name Sequence (5’->3’) 
KCNH1 ex1_Fwd gtttcctgctgtcgtaagaagc ATP6V1B2 ex1_Fwd cgttggcctgcacgcgtttg 
ex1_Rev gaagagctctcctgttaggatg ex1_Rev cttctaaagagacaagtgggtc 
ex2_Fwd tccttacagggcgacatttctg ex2_Fwd aagttgtataggcacagatgtag 
ex2_Rev tcctgtgaatacacactaaatgag ex2_Rev gacacccagtctaaagtatggc 
ex3_Fwd ttcttaatctaacttgagttctttg ex3_Fwd gagggtattgaaagctctcagc 
ex3_Rev tcccaacatacacaagggcttc ex3_Rev atcggactaagtgacactgagc 
ex4_Fwd tgtgataacccagcacttgaag ex4+5_Fwd ctgtaggcatgaacccttgatc 
ex4_Rev ccttctcctaccccgatacac ex4+5_Rev ctatctggcaaaggtacaagac 
ex5_Fwd agagtgactcatgggagcttag ex6_Fwd atgtagttctggtcttctggtg 
ex5_Rev gattagcacactagttttgtgcc ex6_Rev gtgaggtaactggattatacaaac 
ex6_Fwd ctcccatacttctttcatacctg ex7_Fwd ggtttcgtttatgattacgattcc 
ex6_Rev atcaagcatgctccctctgttc ex7_Rev tgtacagcttactacaatgttctc 
ex7_Fwd aagggttgcataaaattgcatctc ex8_Fwd gaaggaacaattcaaatctgtagc 
ex7_Rev gctggcactgtagccatttcc ex8_Rev gttaggtccaaatgctgttattac 
ex8_Fwd cctagtagcttggtggtaagag ex9_Fwd tcttttggtttgagtggcctaag 
ex8_Rev gtaaggctgatctagaagcaaac ex9_Rev tctaatcacttctaccaagttgac 
ex9_Fwd agagtgcagtctggcgtagtg ex10_Fwd tggcatgttgaaacaaacatgttg 
ex9_Rev gaagcaatctctaactgaaggtg ex10_Rev tgttctcaaaataacttcaactcg 
ex10_Fwd tttgccttctctgagcccaatc ex11_Fwd gtacagagggactttttgtggg 
ex10_Rev tccatcttctaatctagcaacatc ex11_Rev agattcttaattctggcgctctg 
ex11_Fwd cagccagcatgtggctaacac ex12_Fwd aggaagagacagtaggattcatc 
ex11_Rev tgttggtcatgtggacatatgtg ex12_Rev atcttgatcatttgcatctgtcc 
  ex13_Fwd ctcttgtgaggagaactagagc 
  ex13_Rev gtgacagagcctcttctctaac 
  ex14_Fwd tggataacactgctaagttgg 
  ex14_Rev caacacaaaggtgggaaccg 
 
Table 4. Sequences of the primers used to screen the coding sequences of KCNH1 and ATP6V1B2 genes. 
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Gene Name Sequence (5’->3’) 
ATP6V1C1 ex2_Fwd cactttgcttgagatcctatgc 
ex2_Rev taaatcatgccaatggctggag 
ex3_Fwd tagggagaatttaagatttgtgag 
ex3_Rev ccattccaataagcagagtatac 
ex4_Fwd caaagtcttggtccattttatcc 
ex4_Rev tgagattatgtttcagggaacag 
ex5_Fwd atttcctcaatgccaatttcagc 
ex5_Rev tctaagttgtaaggatttcttctg 
ex6_Fwd aaatgacctcctaaagtcgtgc 
ex6_Rev ccttagtgagcttttctccatg 
ex7_Fwd actaagactaatccctctcaatg 
ex7_Rev ttacgcttggattttatggaaaac 
ex8_Fwd ttgaagtatacttactatagccag 
ex8_Rev tcacaaaggcaagacagcaaac 
ex9+10_Fwd tacttttctcttccacctgtttc 
ex9+10_Rev aagctttagaggaaattcattctg 
ex11_Fwd catgtagaaagtgaattatgcgac 
ex11_Rev aagctgtatgatgatactgataatc 
ex12_Fwd cgttaaccatgattaaagagtatg 
ex12_Rev agggtaaacaatgtaaattactatg 
ex13_Fwd agtgcatacatttagcccagag 
ex13_Rev aagaagcaagcaaaggatactag 
 
Table 5. Sequences of the primers used to screen the coding sequence of ATP6V1C1 gene. 
 
2.7 Haplotype determination 
Case 1 carried two mutations in KCNH1 gene, one in the exon 2 (inherited from the mother) 
and one in exon 7 (de novo). To evaluate the phase of the two variants, a fragment containing 
KCNH1 coding sequence including exons from 2 to 7 was amplified, from cDNA obtained from the 
retrotranscription of total RNA extracted from patient cultured fibroblasts. Retrotranscription was 
performed using the SuperScript III Reverse Transcriptase (ThermoFisher), with random examers. 
The PCR product was cloned into the pCR2.1 TOPO TA Cloning Vector (Invitrogen), and the 
resulting plasmids were transformed into E. coli. Then, individual E. coli clones were picked and 
subjected to colony PCR and Sanger sequencing. 
 
2.8 3D-Modeling 
To preliminarily assess the effect of the mutations found in KCNH1 and ATP6V1B2, 3D-
modeling was performed in collaboration with researchers from the “Department of Sciences and 
Chemical Technologies”, University of ‘Tor Vergata’ of Rome. Homology models of helices S5 
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and S6 of the K+ voltage-gated channel, subfamily H member 1 (KCNH1) were generated, on the 
basis of the available crystallographic structures of homologous proteins, KvAP voltage-dependent 
K+ channel from Aeropyrum pernix, K+ complex of the NaK channel, and the voltage-gated K+ 
channel from Listeria monocytogenes.  
Homology models of the B subunit (isoform 2) of the human V-ATPase (ATP6V1B2) were 
generated, on the basis of the ATPase from Enterococcus hirae. 
 
2.9 Heterologous KCNH1 expression in CHO cells and Xenopus oocytes 
Electrophysiological experiments were performed in collaboration with researchers of the 
“Department of Cellular and Integrative Physiology”, University Medical Center Hamburg-
Eppendorf, of Hamburg (Germany), to test the effect of the mutations found in KCNH1 gene. The 
used techniques are summarized in the following paragraphs. 
cDNAs of wild-type or mutant human KCNH1 (hEAG1, isoform 1) and cDNA encoding EGFP-N1 
(Clontech) were transfected in Chinese hamster ovary (CHO) cells using Lipofectamine 2000 
(Invitrogen) (Schuster et al., 2011). 
cRNA encoding either wild-type KCNH1 channel or the KCNH1 mutant G469R were injected in 
Xenopus oocytes. 
 
2.10 Electrophysiological studies 
Patch-clamp experiments were performed 5–30h after CHO cell transfection or 
microinjection in the conventional whole-cell configuration of the patch-clamp technique. Xenopus 
oocyte currents were recorded with the two-electrode voltage-clamp technique. Patch-clamp data 
processing was performed with PulseFit 8.65 (HEKA), Excel (Microsoft) and Sigmaplot 11.0 
(Systat Software). Current amplitudes were determined as mean values during the last period of the 
2s test pulses or as maximal current amplitude for slightly inactivating current traces. Experimental 
data are given as means ± s.e.m., with n representing the number of experiments from different 
cells. 
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3. Results 
3.1 Clinical features of selected ZLS subjects 
Case 1 (figure 3) is an italian boy, the unique child of unrelated parents and was born at 
term (37 weeks) by vaginal delivery. Birth length was 47cm (3rd-10th centile), weight 2430g (3rd-
10th centile) and occipital-frontal circumference of 33cm (3rd-10th centile). Additional findings at 
birth included absence of the first finger and toenails and mild generalized hypertrichosis. He stood 
up head at 10 months, walked alone at 24 months and said “mama” and “dada” at 12 months. 
Marked delay of the subsequent psychomotor development was noted with severe motor 
impairment, inability to communicate and lack of facial expressiveness. Seizures developed at 8 
months of age in form of generalized stiffening episodes. Such a complication was treated by 
valproic acid and levetiracetam with partial remission of symptoms. At 2 years, brain MRI showed 
mild dilatation of the cavum vergae, and expansion of the subarachnoid spaces at the temporal 
lobes. Appendicular radiographic examination, performed at the same age, demonstrated hypoplasia 
of the 1st distal phalanx at both hands and feet. Standard karyotyping and CGH array were negative. 
At 7 years, amino acid profile repeatedly revealed high plasmatic levels of hypoxanthine and 
xanthine. At examination, he weighted 21kg (25th-50th centile), was height 121cm (25th-50th centile) 
and had an OFC of 51cm (25th-50th centile). Craniofacial anomalies included mildly turricephalic 
skull, arched eyebrows, bilateral eyelid ptosis, long eyelashes, long phyltrum, a large and protruding 
tongue, and gingival hypertrophy with unerupted upper incisors. The nose appeared very soft at 
palpation. Limbs showed anonychia of the thumbs and great toes, hypoplasia of nails of the 5th 
fingers and 4th left finger. The remaining toenails were rudimentary. Pectus carinatum, thoracic 
kyphosis and cervical hirsutism were also noted. Neurologic examination revealed increased 
drooling, facial expressionless, limb hypotonia and hypotrophic skeletal musculature. He was 
definitely assessed as affected by severe cognitive and motor disability (Castori et al., 2013). 
 
 
 
Figure 3. (A-C) CASE 1. Pictures showing facial appearance and gingival enlargement (A), anonychia of the thumbs 
and great toes and nail hypoplasia of the right fifth finger and right second to fifth toes (B, C). 
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Case 2 (figure 4) was the unique female child of an Italian healthy and unrelated couple (30-
year-old mother and 32-year-old father). She was born at term (39 weeks) from normal delivery. 
Birth parameters were length 48cm (25th centile), weight 2800g (9th-25th centile) and OFC 31cm 
(0.4th-2nd centile). At birth, generalized hypotonia, coarse face, hirsutism, and partial anonychia of 
hands and feet were noted. Transfontanellar ultrasound showed periventricular hyperechogenicity. 
Hand and foot radiographs, performed at 2 months, showed absence of the 2nd and 4th-5th distal 
phalanges on both hands, absence of 3rd distal phalanx on the left, severe hypoplasia with triangular 
aspect of 3rd distal phalanx on the right, tapering and mild hypoplasia of 1st distal and 2nd-5th middle 
phalanges on both hands, absence of 2nd-5th distal and 5th middle phalanges, and hypoplasia of 1st 
distal and 2nd-4th middle phalanges on both feet. Psychomotor development was delayed as she 
stood up head at 12 months, sat steady at 24 months, walked with support at 36 months, walked 
alone at 42 months, said first words at 18 months and first three-word sentences at 5 years. The last 
neurologic examination, at 5 years and 2 months, better characterized the intellectual disability as 
borderline (IQ 74) and noted that her communication competence and praxis were delayed, both 
corresponding to 33 months. The patient underwent standard karyotyping and CGH array with 
negative results. At examination, patient’s weight was 30kg (>97th centile), height 115cm (50th-75th 
centile) and OFC 51cm (50th centile). Facial features included widow’s peak, thick and laterally 
flared eyebrows, long eyelashes, mildly upslanting palpebral fissures, prominent nasal septum with 
hypoplastic alae nasi and a vertical cutaneous-cartilagineous ridging on the nasal tip, prominent 
phyltrum, thick helices and ear lobules. Intraoral examination showed gingival hypertrophy of the 
upper and lower alveoli with normally erupted decidual teeth. The nose and ear cartilages were 
extremely soft at palpation. Hands and feet showed complete anonychia. The neck was short. The 
thumbs were elongated. Hirsutism was evident at back, and upper and lower limbs. The patient also 
displayed mild hypotonia and generalized joint hypermobility (Castori et al., 2013). 
 
 
 
Figure 4. (A-D) CASE 2. Pictures showing facial appearance and gingival enlargement (A,D), anonychia of the fingers 
of hands and feet, and hypoplasia of the terminal phalanges (B,C). 
 
24 
 
Case 3 (figure 5) was the first daughter of two Italian non-consanguineous and healthy 
parents. At birth her weight was 3070g (52th centile), and length was 51cm (84th centile). The OFC 
measurement is not reported. At examination she was 12 years old, and her parameters were weight 
62.5kg (96th centile), height 155cm (71th centile), and OFC 56cm (97th centile). IQ test gave a low 
score, 55. At 6 months she started with episodes of focal epilepsy, controlled with Tegretol, and 
electroencephalographic exam showed bilateral frontotemporal abnormal slow electric activity. 
Ophthalmological examination demonstrated the presence of myopia and oculomotor apraxia. 
Facial characteristics included thick eyebrows, large nose, bulbous nasal tip, thick helix, 
macrostomia, thick upper and lower lip, malocclusion and low frontal hairline. Oral examination 
showed the gingival hyperplasia before anticonvulsant treatment. Limbs were asymmetric. She has 
scoliosis and moderate hirsutism on limbs. Other features were ataxia, intentional tremor, motor 
clumsiness, and two café-au-lait spots. 
 
 
 
Figure 5. (A-C) CASE 3. Pictures showing facial appearance (A), absent aplasia of fingers and terminal phalanges of 
hands and feet (B,C). 
 
The three patients’ clinical features highlight the great clinical variability of ZLS phenotype. 
Intellectual disability ranges from very mild (case 2) to severe intellectual disability (case 1). 
 Hypotonia is present in two cases (case 1 and 2). Epilepsy is present in cases 1 and 3. Ataxia 
was present in two cases (case 1 and 3). Gingival hyperplasia was present in all the three patients, 
while hypoplasia of nails and terminal phalanges were present only in cases 1 and 2. The three 
patients share a coarse face with anomalies of ears and nose cartilages, with a more pronounced 
phenotype in case 2, showing a peculiar nose (figure 4A). Hirsutism was present in all affected 
subjects. The comparison among the first three patients studied in this research project is 
summarized in table 6. 
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Table 6. Summary of the features of the first three analyzed patients. 
M = male; F = female; + = present; - = absent; ID = intellectual disability; NA = not assessed; ND = not documented. 
 
3.2 Whole-exome sequencing data analysis 
WES data analysis allowed to detect a mean coverage of 99.4%, 98.3%, and 99.6% with a 
mean depth on target of respectively 56x, 57x, and 83x for the three patients, respectively (table 7). 
The number of total variants identified in the three proband was:  68672, 63874, and 82500, for 
cases 1, 2 and 3, respectively. 
 Assuming that this severe phenotype is caused by variants having a great impact on the 
function of the protein or in the maturation of the transcript, we filtered 10861, 10652, and 10698 
high-quality variants with a functional effect (missense, frameshift, stop-gained, stop-loss, start-
gained, start-loss, intronic variants located 5 nucleotides from the exon variants), according to 
UnifiedGenotyper and HaplotypeCaller algorithms.  
Since the disease is very rare, we filtered only variants not present, or annotated with a very 
low frequency in population databases (dbSNP, ExAC and in-house database) narrowing down the 
number of candidate variants. 348, 310, and 347 variants were selected as novel, clinically 
associated, or with low/unknown frequency.  
Variants were then classified based on genotype (table 7), assuming an autosomal dominant or 
recessive mode of inheritance. 
In case 1, we found one homozygous variant in KDM6B, and 32 compound heterozygous 
variants in 15 genes. For those variants we were not able to predict their phase as we had only 
sequenced the exome of the proband. For the same reason, it was not possible to assess variants 
with a de novo onset. 
In case 2, there were two compound heterozygous variants in EPPK1, and one predicted de 
novo variant in ATP6V1B2 gene. 
Subject Case 1 Case 2 Case 3 
Sex M F F 
ID +++ + ++ 
Seizures + − + 
Hypotonia + + - 
Hearing loss NA − NA 
Coarse face + ++ + 
Gingival enlargement + + + 
Aplastic/hypoplastic nails + + − 
Aplastic/hypoplastic terminal phalanges + + − 
Scoliosis + ND + 
Hypertrichosis + + + 
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In case 3, we found 6 predicted compound heterozygous variants in EVPL, KIF7, and 
SNX27, and 3 predicted de novo variants in EVPL, TP53I3, and KCNH1 genes. 
 
Case 1 2 3 
Target region coverage 99.4% 98.3% 99.6% 
Average sequencing depth 56x 57x 83x 
Total variants 68672 63874 82500 
Nonsynonymous, 
splice variants (+/-5) 10861 10652 10698 
Novel, clinically associated,  
unknown/low frequency variants 348 310 347 
Predicted homozygous variants 1 0 0 
Predicted compound heterozygous variants 32
a 
(15 genes) 
2 
(1 gene) 
6 
(3 genes) 
Predicted de novo variants / 1 3 
 
Table 7. Results of the exome sequencing of the first three patients (Cases 1, 2, and 3). Number of variants obtained 
from the exome sequencing experiments, classified by mode of inheritance. aSince we sequenced only the proband, we 
were not able to establish the phase of those variants. 
 
3.3 Selection of candidate variants 
The selection of the candidate variants was based on mode of inheritance, sharing of 
variants/genes among patients, and deleteriousness of the variants, as described in “Materials and 
methods” section. 
Among all the identified variants, we considered at first the variants/genes shared by at least 
two patients. This approach led to the identification of three different variants in the same gene 
(KCNH1) in cases 1 and 3. Case 1 carried two variants in heterozygosis, c.125T>C (p.I42T), and 
c.1054C>G (p.L352V), case 2 c.1405G>A (p.G469R) (NM_002238, NP_002229). The c.125T>C 
(p.I42T) variant in KCNH1 was annotated in ExAC with a minor allele frequency of 0.0008% 
(rs772076205). In case 2, the best candidate variant was a predicted de novo variant in ATP6V1B2 
gene, c.1454G>C (p.R485P) (NM_001693, NP_001684) (table 8).  
 
Case Zygosity Gene Genomic 
position 
Nucleotide 
Change 
Amino acid 
Change 
rs ID 
1 Compound Heterozygous KCNH1 
Chr1:211280674 c.125T>C p.I42T rs772076205 
Chr1:211093309 c.1054C>G p.L352V . 
2 De novo ATP6V1B2 Chr8:20077831 c.1454G>C p.R485P . 
3 De novo KCNH1 Chr1:210977485 c.1405G>A p.G469R . 
 
Table 8. Selected candidate variants. The mode of inheritance, the genomic position and the variant position on the 
transcript and protein are indicated. 
 
27 
 
All the above mentioned variants in the KCNH1 and ATP6V1B2 genes were predicted to be 
“probably damaging” by Polyphen, “damaging” by SIFT, and the CADD score predicted a 
deleterious effect (table 9). 
 
Case Gene Nucleotide 
change 
Amino acid 
change 
Polyphen 
prediction 
SIFT 
prediction 
CADD 
score 
1 KCNH1 
c.125T>C p.I42T Probably damaging Damaging 27 
c.1054C>G p.L352V Probably damaging Damaging 25.3 
2 ATP6V1B2 c.1454G>C p.R485P Probably damaging Damaging 34 
3 KCNH1 c.1405G>A p.G469R Probably Damaging Damaging 34 
 
Table 9. Predicted effect of the candidate variants is summarized, as evaluated by Polyphen, SIFT, and CADD. 
 
3.4 Validation of candidate variants 
All the selected variants were analyzed in the probands and their parents through Sanger 
sequencing and their segregation was confirmed. 
In case 1, one of the two variants in KCNH1, c.125T>C; p.I42T, resulted to be inherited 
from the mother, while the other, c.1054C>G; p.L352V, resulted to be de novo. The germline origin 
of the de novo variants was confirmed through Sanger sequencing on DNA extracted from blood, 
hair bulb and/or buccal cells (figure 6). The paternity and maternity were confirmed in the three 
patients. 
 
 
 
Figure 6. Sequence electropherograms showing the de novo origin of the identified KCNH1 and ATP6V1B2 missense 
mutations in cases 1, 2, and 3 (indicated by red arrows). The heterozygous state of three mutations was documented in 
peripheral leukocytes, hair bulb and/or buccal cells of cases 1 and 3 indicating germline origin. An additional previously 
annotated heterozygous KCNH1 variant, c.125T>C (p.Ile42Thr), was present in case 1 and his healthy mother 
(indicated by blue arrows). 
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3.5 Haplotype analysis 
Case 1 carried two variants in KCNH1 gene, c.125T>C; p.I42T, inherited from the mother, 
and c.1054C>G; p.L352V, with a de novo onset. In order to characterize the phase of the two 
variants, amplification of cDNA from patient fibroblasts was performed allowing to detect that the 
c.125T>C variant was in cis with the c.1054C>G variant, demonstrating the onset of the de novo 
variant on maternal allele.  
During colony screening through Sanger sequencing a further KCNH1 isoform, not 
annotated in EST database (https://www.ncbi.nlm.nih.gov/genbank/) and lacking of exon 6, was 
identified. Preliminary expression analysis through retrotranscription of RNA from fetal and adult 
brain and fibroblast suggest that an isoform encompassing exons 1-11 and lacking exon 6 is 
expressed at least in those tissues. This transcript could potentially lead to the translation of a 
protein lacking the amino acids 187-344 corresponding to the first three transmembrane helices. 
Gene expression and biochemical studies are ongoing to better characterize this isoform in terms of 
expression, localization, and function. 
 
3.6 Enlargement of the ZLS cohort 
3.6.1 Clinical features 
An international collaboration allowed us to extend the cohort of ZLS patients with 5 further 
patients. Three of them (cases 5, 6, and 8) were reported by Abo-Dalo and co-workers (2008), while 
the other two have never been reported before (figure 7). These five patients present the following 
clinical features:  
Case 4: a German girl with severe intellectual disability and autism, hypotonia, generalized 
tonic clonic seizures, asymmetric cerebral ventricles, macrocephaly, long and coarse face, gingival 
hyperplasia, hypoplastic terminal phalanges of hands and feet, aplastic or hypoplastic nails, thoracic 
scoliosis, and hypertrichosis. 
Case 5: an Australian boy with profound intellectual disability, hypotonia, seizures, coarse 
face, thick scalp hair and eyebrows, broad forehead, broad nasal tip, short philtrum, thick lips, large 
ears with anteverted and thickened ear helices, gingival hyperplasia, aplastic or hypoplastic nails, 
and severe scoliosis (Abo-Dalo et al., 2008). 
Case 6: an Australian girl with profound intellectual disability, hypotonia, seizures, 
macroglossia, central incisor, arched eyebrows, gingival hyperplasia, hypoplastic terminal 
phalanges and aplastic nails of hands and feet, and thoracic scoliosis (Abo-Dalo et al., 2008). 
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Case 7: an Indian female with severe intellectual disability, neonatal seizures, sensorineural 
hearing loss, bilateral horizontal nystagmus, low set ears, high forehead, pointed nose, prominent 
alae nasi, mild hypertelorism, epicanthal folds, long philtrum, large lower lips, down turned angle 
of mouth, hypoplasia of terminal phalanges, and bilateral nail aplasia/hypoplasia. 
Case 8: a French boy with severe intellectual disability, hypotonia, encephalopathy, 
unilateral total deafness, coarse face, thick scalp hair, synophrys, large bulbous nose with “bifid” 
nasal tip, thick lips, macroglossia, gingival hyperplasia, aplastic terminal phalanges and nails of 
hands and feet, severe kyphosis/lordosis, and hypertrichosis (Abo-Dalo et al., 2008). 
 
 
 
Figure 7. Clinical features of the additional ZLS-affected individuals (A, F) Facial phenotype of cases 4, 6, and 8: (A) 
case 4, (F) case 6, (H) case 8. Note the gingival enlargement in case 6. (B, C) Case 4 shows anonychia of the right great 
toe and hypoplastic nails of all other right toes and fingers of left hand. (D, E) Case 5 shows aplastic nails of the thumb 
and first to third toes and hypoplastic nails of all other fingers and toes. (G) Case 7 shows anonychia of the left great toe 
and hyponychia of all other toes. (I) Gingival enlargement in case 8. (J, K) Case 8 shows aplastic terminal phalanges of 
the second and fifth fingers on the left hand, the fifth finger on the right hand and all toes except the first. 
Hypertrichosis can be observed in case 8 (J, K). 
 
3.6.2 Whole-exome sequencing results 
WES was performed on cases 4 and 8 and data analysis allowed to detect a mean coverage 
of 97.7%, and 98.6% with a mean depth on target of respectively 36x, and 52x for the two patients, 
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respectively. Among the total variants (70894, and 81294), 9542, and 10693 high-quality variants 
with a functional effect (missense, frameshift, stop-gained, stop-loss, start-gained, start-loss, 
intronic variants located 5 nucleotides from the exon variants) were predicted by UnifiedGenotyper 
and HaplotypeCaller algorithms for each case. After frequency filtering, 227, and 268 were selected 
as novel, clinically associated, or with low/unknown frequency. Variants were then classified based 
on genotype. In case 4, we found two predicted homozygous variants in IL4R, and CAPN15, 4 
predicted compound heterozygous variants in DNMBP and RGS3, and 6 predicted de novo variants 
in IKZF2, CLK4, SDK1, SLC38A2, VPS13C, and KCNH1. 
In case 8, there were 4 predicted compound heterozygous variants in CPXM2, and HSPG2, 
and 7 predicted de novo variant in CFHR5, PMS2, TJP2, DNAJC25-GNG10, NAV3, GP1BA, and 
ATP6V1B2 (table 10). 
 
Case 4 8 
Target region coverage 97.7% 98.6% 
Average sequencing depth 36x 52x 
Total variants 70894 81294 
Nonsynonymous, 
splice variants (+/-5) 9542 10693 
Novel, clinically associated,  
unknown/low frequency variants 227 268 
Predicted homozygous variants 2 0 
Predicted compound heterozygous variants 4 (2 genes) 
4 
(2 genes) 
Predicted de novo variants 6 7 
 
Table 10. Results of the exome sequencing of cases 4 and 8. Number of variants obtained from the exome sequencing 
experiments, classified by mode of inheritance. 
 
3.6.3 Selection of candidate variants 
The selection of the candidate variants was based on mode of inheritance, sharing of 
variants/genes among patients, and deleteriousness of the variants. 
Among all the identified variants, we considered at first the variants/genes shared with the 
previously analyzed exomes. This approach led to the identification of a variant in KCNH1 gene in 
case 4, c.1399A>G (p.I467V) (NM_002238, NP_002229). The variant found in KCNH1 has never 
been reported in dbSNP or ExAC. In case 8, the same variant in ATP6V1B2 found in case 2, 
c.1454G>C (p.R485P) (NM_001693, NP_001684) was identified (table 11). 
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Case Zygosity Gene Genomic position 
Nucleotide 
change 
Amino acid 
change 
rs 
ID 
4 De novo KCNH1 Chr1:210977491 c.1399A>G p.I467V . 
8 De novo ATP6V1B2 Chr8:20077831 c.1454G>C p.R485P . 
 
Table 11. Selected candidate variants. The mode of inheritance, the genomic position and the variant position on the 
transcript and protein are indicated. 
 
3.6.4 Validation of candidate variants and Sanger sequencing screening 
All the selected variants were analyzed in the probands and their parents through Sanger 
sequencing and their segregation was confirmed.  
The variant found in case 4 in KCNH1 gene, c.1399A>G; p.I467V, and the variant identified 
in case 8 in ATP6V1B2 gene, c.1454G>C; p.R485P, resulted to be de novo (figure 8). The paternity 
and maternity were confirmed in the two patients. 
In addition, a Sanger sequencing screening of the coding sequences of KCNH1 and 
ATP6V1B2 genes in the cases 5, 6, and 7 allowed us to identify a patient with two new de novo 
variants in cis, c.[974C>A;1066G>C], p.[S325Y;V356L], one patient with one new de novo variant, 
c.1042G>A (p.G348R), and one patient with a de novo variant already identified, c.1399A>G 
(p.I467V) in case 4, in KCNH1 (figure 8 and 9). Those variants resulted not to be annotated in 
dbSNP and ExAC (table 12). 
 
Case Zygosity Gene Genomic 
position 
Nucleotide 
change 
Amino acid 
Change 
rs ID 
5 De novo KCNH1 Chr1:211093389; 
211093297 
c.[974C>A; 
1066G>C] 
p.[S325Y; 
V356L] 
. 
6 De novo KCNH1 Chr1:211093321 c.1042G>A p.G348R . 
7 De novo KCNH1 Chr1:210977491 c.1399A>G p.I467V . 
 
Table 12. Variants identified in cases 5, 6 and 7 through Sanger sequencing screening of the coding sequence of 
KCNH1 and ATP6V1B2 genes. The mode of inheritance, the genomic position and the variant position on the transcript 
and protein are indicated. 
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Figure 8. Sequence electropherograms showing the de novo origin of the identified KCNH1 and ATP6V1B2 missense 
mutations in cases 4-8 (indicated by red arrows). The heterozygous state of three mutations was documented in 
peripheral leukocytes for all samples and in buccal cells in case 8. 
 
 
 
Figure 9. By cloning the KCNH1 exon 7–containing amplicon of case 5 followed by sequencing, we determined the 
haplotypes and found that the two identified de novo changes c.974C>A and c.1066G>C are in cis (wild-type allele 
above, and mutated KCNH1 allele below in the figure; mutated nucleotides are framed). 
 
The c.1399A>G (p.I467V) variant in KCNH1 was predicted to be “probably damaging” by 
Polyphen, and deleterious according to CADD score. SIFT predicted this variant as “tolerated”. The 
c.974C>A (p.S325Y) variant in KCNH1 was predicted as “possibly damaging” by Polyphen, 
“damaging” by SIFT and deleterious by the CADD scoring system. The c.1066G>C (p.V356L) 
variant in KCNH1 was predicted as “benign” by Polyphen, “tolerated” by SIFT, and deleterious 
according to the CADD score. Finally, the c.1042G>A (p.G348R) variant in KCNH1 was predicted 
as “probably damaging” by Polyphen, “damaging” by SIFT, and deleterious by the CADD score 
(table 13). 
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Case Gene Nucleotide Change 
Amino acid 
Change 
Polyphen 
prediction 
SIFT 
prediction 
CADD 
score 
4, 7 KCNH1 c.1399A>G p.I467V Probably damaging Tolerated 24.7 
5 KCNH1 c.974C>A p.S325Y 
Possibly 
damaging Damaging 24.6 
c.1066G>C p.V356L Benign Tolerated 21.9 
6 KCNH1 c.1042G>A p.G348R Probably damaging Damaging 31 
 
Table 13. Predicted effect of the mutations identified in the patients enclosed in the enlarged cohort is summarized, as 
evaluated by Polyphen, SIFT, and CADD. 
 
All the identified variants were highly conserved across eukaryotes, figure 10. 
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Figure 10. Multiple protein sequence alignments around the KCNH1 and ATP6V1B2 amino acid substitutions from 
different species. Alignment of the regions flanking the detected missense variants in orthologous proteins, showing the 
evolutionary conservation of amino acids S325, G348, L352, V356, I467 and G469 in human KCNH1 (NP_002229) 
and of R485 in human ATP6V1B2 (NP_001684). Multiple alignments were gathered from 
http://www.ncbi.nlm.nih.gov/homologene/. Conserved residues have a red background, and non‐conserved residues 
have a gray background. Amino acid sequence alignments demonstrate high (S325 and V356 in human KCNH1) or 
complete (G348, L352, I467 and G469 in human KCNH1 and R485 in human ATP6V1B2) evolutionary conservation 
of the altered residues. 
 
3.7 ZLS cohort: summary of the clinical features  
All the patients analyzed through WES and Sanger sequencing and found to be mutated in 
KCNH1 and ATP6V1B2 genes show intellectual disability, and coarse face. Deafness was present in 
2/8 cases, gingival hyperplasia and hypoplastic nails/phalanges in 7/8 cases, scoliosis in 6/8 cases, 
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hirsutism in 5/8 (tables 14 and 15). Worth to be noted, seizures is present only in the six patients 
harboring KCNH1 mutations (table 14). The two patients (cases 4 and 7) with the c.1399A>G 
(p.I467V) variant in KCNH1 have in common severe intellectual disability, seizures, a coarse face, 
and hypoplastic nails and phalanges, the hypoplasia of phalanges is less marked in case 7 than in 
case 4. The two patients mutated in ATP6V1B2 (case 2 and 8) both have intellectual disability, a 
very similar coarse face, gingival hyperplasia, hypoplastic nails and phalanges, and marked 
generalized hirsutism. Intellectual disability was mild in case 2 and severe in case 8, gingival 
hyperplasia was less marked in case 2 than in case 8. 
 
Gene KCNH1 
Mutation 
(NM_002238) 
c.1054C>G 
p.L352V 
c.1405G>A 
p.G469R 
c.1399A>G 
p.I467V 
c.[974C>A;1066G>C] 
p.[S325Y;V356L] 
c.1042G>A 
p.G348R 
Mutation 
(NM_172362) 
c.1135C>G 
p.L379V 
c.1486G>A 
p.G496R 
c.1480A>G 
p.I494V 
c.[1055C>A;1147G>C] 
p.[S352Y;V383L] 
c.1123G>A 
p.G375R 
Case 1 3 4 7 5 6 
Sex M F F F M F 
ID + + + + + + 
Seizures + + + + + + 
Hypotonia + - + - + + 
Deafness NA NA - + - - 
Coarse face + + + + + + 
Gingival 
hyperplasia + + + - + + 
Hypoplastic 
nails + - + + + + 
Hypoplastic 
phalanges + - + + - + 
Scoliosis + + + ND + + 
Hirsutism + + + - - - 
 
Table 14. Summary of the mutations identified in KCNH1 in this work (reported in Kortum et al., 2015), and clinical 
features of the analyzed patients. Mutations are reported according to both the isoforms. 
M = Male, F = Female, ID = Intellectual Disability, NA = Not Assessed, ND = Not Documented 
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Gene ATP6V1B2 
Mutation (NM_001693) c.1454G>C p.R485P 
Case 2 8 
Sex F M 
ID + + 
Seizures - - 
Hypotonia + + 
Deafness - + 
Coarse face + + 
Gingival hyperplasia + + 
Hypoplastic nails + + 
Hypoplastic phalanges + + 
Scoliosis - + 
Hirsutism + + 
 
Table 15. Summary of the mutations identified in ATP6V1B2 in this work (reported in Kortum et al., 2015), and 
clinical features of the analyzed patients. M = Male, F = Female, ID = Intellectual Disability 
 
3.8 KCNH1: structural and functional studies results 
The KCNH1 gene is located on the long arm of chromosome 1. Alternative splicing of this 
gene results in two transcript variants encoding distinct isoforms (NM_172362 and NM_002238), 
that differ in the coding sequence for 81 nucleotides in length. The encoded protein is a member of 
the potassium channel, voltage-gated, subfamily H protein (also called Kv10.1). This member is a 
pore-forming subunit of a voltage-gated non-inactivating delayed rectifier potassium channel. The 
functional channel is a homotetramer constituted by 7 transmembrane helices, and a hairpin 
structure (known as the pore-forming loop, P-loop). It is highly expressed in myoblast and brain, 
and activates at the onset of myoblast differentiation. Five of six mutations that we found in ZLS 
patients are located in the two helices involved in the opening of the channel, one mutation maps in 
the voltage-sensor helix (figure 11). 
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Figure 11. Schematic view of the KCNH1 channel showing the location of the residues affected in individuals with 
ZLS (colored dots). The S4 segment acts as voltage-sensor domain, and the assembly of four subunits is required to 
form a functional channel. cNBD, cyclic nucleotide-binding domain; EAG, EAG domain; P, pore region 
 
In collaboration with Prof. Lorenzo Stella’s research group of Tor Vergata, the KCNH1 
mutations were characterized from the structural point of view using a homology model. The 
affected amino acid residues of KCNH1 were located in the voltage-sensing S4 helix (S325), the 
S4–S5 linker (G348), and the S5 (L352 and V356) and S6 (I467 and G469) segments. The p.G469R 
change is predicted to impair tetramer formation or favour the open state with a lower conductance 
due to the presence of cationic residues close to the channel pore. L352, V356 and I467 form a tight 
hydrophobic cluster in the open structure, which rearranges in the closed conformation. 
Perturbations of these residues, are predicted to affect the closed/open transition (figure 12). 
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Figure 12. Structural impact of ZLS-associated KCNH1 mutations. (A) Model of helices S5 and S6 of KCNH1 in their 
closed state (viewed from the intracellular side of the membrane). Affected residues (yellow) and K+ (gray sphere) are 
shown. (B) Model of helices S5 and S6 of KCNH1 in their open state. The color code is as in a. (C) Enlargement of the 
pore-closing region in the closed state. Atoms are shown as spheres to illustrate the steric hindrance of this region, 
which would hardly accommodate a larger charged residue, such as arginine, at position 469. (D) Enlargement of the 
hydrophobic cluster formed by L352, V356 and I467 (side chains shown in sphere representation) in the open state. 
 
In collaboration with a research group of the University of Hamburg, functional 
consequences of the ZLS-associated KCNH1 mutations by patch-clamp experiments on CHO cells 
expressing wild-type and mutant KCNH1 channels were assessed. The current amplitudes of the 
mutants did not differ significantly from the amplitudes of wild-type KCNH1; all mutant channels, 
however, exhibited a remarkable shift in the activation threshold to more negative potentials, 
producing dramatic increases in whole-cell K+ conductance in the negative-potential range (the 
G469R change gives this result when the mutated protein is co-expressed with the wild type 
protein). In comparison to wild-type channels, the mutants exhibited accelerated channel activation 
and slower deactivation. Together, these data show a potential gain-of-function effect for the 
disease-associated KCNH1 mutants (figure 13). 
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Figure 13. Voltage-dependent activation of human wild-type (WT) and mutant KCNH1 channels expressed in CHO 
cells. (A) Families of whole-cell currents elicited with 2-s variable test pulses as indicated in the pulse protocol shown 
at the right below the current traces. For the L352V mutant, a more negative holding potential of −100 mV and test 
pulses starting from −120 mV were used. Expression of the G469R mutant did not result in recordings of voltage-
dependent K+ currents (n = 22). Zero current is indicated by dashed lines and arrowheads. (B) Mean (±s.e.m.) KCNH1 
current amplitudes as a function of the test pulse potential. Current amplitudes were normalized to the maximum 
amplitude recorded at +60 mV. Data points were connected by straight lines. The inset shows current amplitudes at +40 
mV normalized to the mean current for the wild-type channel. (***P < 0.001, significantly different from wild type) (C) 
Mean (±s.e.m.) normalized whole-cell conductance as a function of the test pulse potential. Lines represent fourth-order 
Boltzmann functions fitted to the data points. Numbers of experiments are shown in parentheses. (D) Mean (+s.e.m.) 
values of the potential of half-maximal KCNH1 channel activation (V0.5 activation), derived from fits to permeability 
data considering the Goldman-Hodgkin-Katz current equation. One-way ANOVA with post-hoc Bonferroni t testing 
yielded significant (***P < 0.001) differences for all combinations except the one indicated (NS, not significant). 
 
3.9 ATP6V1B2: 3D studies results 
The ATP6V1B2 (ATPase H+ Transporting V1 Subunit B2) gene encodes a non-catalytic 
subunit of the peripheral V1 complex of vacuolar ATPase, a multisubunit enzyme that mediates 
acidification of eukaryotic intracellular organelles, and is located on the short arm of the 
chromosome 8. V-ATPase is composed of a cytosolic V1 domain and a transmembrane V0 domain. 
The V1 domain contains the ATP catalytic site. The p.R485P mutation falls at the interface between 
subunits B and A (figure 14). 
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Figure 14. Schematic view of the subunit structure of the V-ATPase. The catalytic V1 complex consists of the A, B, C, 
D, E, F, G and H subunits. The V0 domain is membrane embedded and is composed of a characteristic C-ring structure 
with which the a, d and e subunits are associated. R485 is highlighted by a blue dot. 
 
To explore the structural impact of the p.R485P amino acid change a homology model of the 
B2 subunit was generated and inserted  into the crystallographic structure of the A3B3 hexamer of 
the Enterococcus hirae ATPase. p.R485P substitution is not expected to affect the affinity of the 
protein for the ATP. R485 is however located in an α-helical segment that is predicted to be 
disrupted by substitution to proline. Overall, the arginine-to-proline substitution is predicted to 
perturb intersubunit interactions within the V1 subcomplex by destabilizing the C-terminal segment 
of the B subunit (figure 15). 
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Figure 15. Structural impact of ZLS-associated ATP6V1B2 mutation. (A) Homology model of the B subunit of the 
human V-ATPase (ribbon representation) in the context of the A3B3 hexamer of the E. hirae ATPase (surface 
representation, with A subunits colored in salmon and B subunits colored in light blue). The complex is shown as seen 
from the membrane surface. One of the B subunits was substituted by the homology model of the B subunit of the 
human V-ATPase (ribbon representation). ATP analogs are shown in green, and R485 is represented in yellow. (B) 
Enlargement of the A-B interface. R485 and D507 are shown in stick representation. The C-terminal segment of the B 
subunit predicted to be destabilized by the p.R485P substitution is represented in yellow. The space-filling model of 
residues 485–511 is also shown, as a semitransparent white surface. 
 
3.10 Further ZLS cohort enlargement 
With the aim of disclosing the presence of additional KCNH1/ATP6V1B2 mutations or new 
genes mutated in patients with features of ZLS phenotypic spectrum and to better characterize 
molecular bases, we recruited 4 additional patients. These patients have clinical features strongly 
suggestive of ZLS, like coarse face, gingival hyperplasia, hypertrichosis, aplasia/hypoplasia of nails 
and terminal phalanges. 
Sanger sequencing screening of the entire coding sequences of KCNH1 and ATP6V1B2 
genes in the probands resulted to be negative, suggesting genetic heterogeneity.  
Therefore, we decided to perform a WES approach in two patients (case 9 and 10) and their 
respective parents (figures 16 and 17). While in case 10 the WES data analyses are still ongoing, for 
the case 9, results are reported in the following section. 
Case 9 has intellectual disability, a bulbous soft nose with a bifid tip, malformation of the 
cartilage ears, nail aplasia of hands and feet, and hypoplastic terminal phalanges. Worth of noting, 
the father presented some clinical features present in his daughter but in a milder form, as a bulbous 
nose, and hypoplastic nails and terminal phalanges of hands and feet (figure 16).  
 
 Figure 16. Comparison among phenotypic features of c
complete lack of nails, while father’s feet and hands show
and her father (F) are very similar. 
 
Figure 17. Pictures showing some of the features of case 10. Long eyebrows, m
corners of the mouth, limbs and back hypertrichosis
 
3.11 WES data analysis results
WES data analysis of case 9
a mean depth of 111x. Among the 
functional effect (missense, frameshift, stop
variants located five nucleotides from the exon variants)
with low/unknown frequency variants
disclosing the presence of six com
and SERPINA10) and four de novo
16). 
 
 
 
 
 
 
 
 
 
A B 
 
ase 9 and her father. Feet and hands of c
 hypoplastic nails (B,D). The nose shape of 
ild facial hypertrichosis
. 
 
 allowed to obtain a coverage of 97% of the target regions
73379 total variants, 13431 were of high
-gained, stop-loss, start-gained, start
. 442 were novel, clinically associated, or 
. Variants were then classified based on
pound heterozygous variants in three genes
 variants, in TMEM247, ATP6V1C1, and
C D E 
42 
 
ase 9 (A,C) show 
the proband (E) 
 
, downturned 
 with 
 quality and had a 
-loss, intronic 
 the genotype, 
 (CCDC86, DNAH11, 
 SARAF genes (table 
F 
43 
 
Case 9 
Target region coverage 97% 
Average sequencing depth 111x 
Nonsynonymous, 
splice variants (+/-5) 13431 
Novel, clinically associated, 
unknown/low frequency variants 442 
Predicted homozygous variants 0 
Predicted compound heterozygous variants 6 (3 genes) 
Predicted de novo variants 4 
 
Table 16. Results of the exome sequencing of case 9. Number of variants identified in the exome, classified by mode of 
inheritance. 
 
3.12 Variants analysis and selection of candidate genes 
Variants and genes identified in the previous step were analyzed in details in order to select 
the best candidate variant/s. The genes harboring the compound heterozygous variants were 
excluded for several reasons, i.e. frequency in population database, gene expression and protein 
function. The de novo variants in SARAF and TMEM247 genes were excluded because they were 
artifacts due to a misalignment of the reads. The best candidate was a predicted de novo variant 
c.865G>A, p.E289K, that affects a highly conserved amino acid in ATP6V1C1 gene (NM_001695, 
NP_ 001686) (figure 18), coding for an interactor of ATP6V1B2 subunit (table 17). 
 
Case Zygosity Gene Genomic 
position 
Nucleotide 
change 
Amino acid 
change 
rs 
ID 
9 De novo ATP6V1C1 Chr8:104076978 c.865G>A p.E289K . 
 
Table 17. New candidate gene identified by WES of the patient added to the ZLS cohort. The mode of inheritance, the 
genomic position and the variant position on the transcript and protein level are indicated. 
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Figure 18. Multiple protein sequence alignments near the ATP6V1C1 amino acid substitution from different species. 
Alignment of the regions flanking the detected missense variant in orthologous proteins, showing the evolutionary 
conservation of amino acid E289 in human ATP6V1C1 (NP_001686). Multiple alignment was gathered from 
http://www.ncbi.nlm.nih.gov/homologene/. Conserved residues have a red background, and non‐conserved residues 
have a gray background. Amino acid sequence alignments demonstrate a highly evolutionary conservation of the altered 
residue. 
 
This variant was predicted as “possibly damaging” by Polyphen, “damaging” by SIFT, and 
deleterious according to the CADD score (table 18). 
 
Case Gene Nucleotide 
Change 
Amino acid 
change 
Polyphen 
Prediction 
SIFT 
prediction 
CADD 
score 
9 ATP6V1C1 c.865G>A p.E289K Possibly 
damaging 
Damaging 36 
 
Table 18. Predicted effect of the newly identified variant in case 9 according to Polyphen, SIFT, and CADD. 
 
3.13 Validation of candidate variant 
Sanger sequencing confirmed the presence of the variant in the proband in DNA extracted 
from blood, hair bulb, and buccal cells (figure 19).  
The presence in the father of case 9 of some features fitting with ZLS syndrome suggested 
the presence of the pathogenic variant also in this subject, probably with a lower percentage of cells 
carrying the mutation.  
Electropherograms of the region encompassing ATP6V1C1 variant of the father disclosed 
the presence of the variant allele in a low proportion in DNA from different tissues (blood, hair 
bulb, buccal cells) (figure 19A). A manual inspection, using the Integrative Genomics Viewer 
(IGV) of reads aligning in this region of father WES, disclosed the presence of 6 reads with the 
variant allele versus 85 reads carrying the wild-type allele (figure 19B). The c.865G>A (p.E289K) 
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variant was not detected by variant calling algorithms used in the WES analysis pipeline probably 
due to the low abundance of the variant allele. When we applied a different pipeline (MuTect2, 
Cibulskis et al., 2013) from the GATK package, a somatic SNP and indel caller that takes into 
account the presence of mosaicism, the ATP6V1C1 variant allele was identified also in the father 
(figure 19B). 
 
 
 
Figure 19. (A) Electropherograms showing the mutation in ATP6V1C1 gene in the proband’s cells and, with variable 
proportion, also in the father. (B) Reads from father WES alignment with IGV disclosing the presence of low copy 
number reads harboring the variant allele. 
 
3.14 ATP6V1C1 gene 
ATP6V1C1 (ATPase H+ Transporting V1 Subunit C1), is located on the long arm of 
chromosome 8, and encodes a component of vacuolar ATPase (V-ATPase). ATP6V1C1 is one of 
two genes encoding the V1 domain C subunit proteins and is ubiquitously expressed. The subunit C 
is necessary for the assembly of the catalytic sector of the enzyme and is likely to have a specific 
function in its catalytic activity. ATP6V1C1 is an essential component of the osteoclast proton 
pump and in F-actin ring formation in osteoclasts (Feng et al., 2009). In figure 20 the structure of 
the V-ATPase is represented and the subunit affected by the mutation is indicated. 
Structural analyses are ongoing to characterize the effect of the ATP6V1C1 mutation on the 
ATPase assembly/function. 
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Figure 20. Schematic view of the subunit structure of the V-ATPase. The catalytic V1 complex consists of the A, B, C, 
D, E, F, G and H subunits. The V0 domain is membrane embedded and is composed of a characteristic C-ring structure 
with which the a, d and e subunits are associated. The subunit affected by the p.E289K is indicated by a red arrow. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E289K 
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4.  Discussion 
Zimmermann-Laband Syndrome (ZLS), firstly described in 1928 by Zimmermann, is 
characterized by gingival fibromatosis, dysplastic or absent nails, hypoplasia of the distal 
phalanges, scoliosis, hepatosplenomegaly, hirsutism, and abnormalities of the cartilage of the nose 
and/or ears. To date, about 40 patients have been described with features fitting ZLS.  
ZLS belongs to a group of clinically overlapping and genetically heterogeneous syndromes, 
such as Temple-Baraitser syndrome (TMBTS), dominant deafness-onychodystrophy syndrome 
(DDOD), deafness, onychodystrophy, osteodystrophy, mental retardation, seizures syndrome 
(DOORS), and Cantu syndrome (CS). Intellectual disability, epilepsy, deafness, hypoplasia or 
aplasia of nails and/or terminal phalanges, and gingival enlargement vary among the different 
disorders as well as within each condition. 
With the aim of identifying ZLS causative gene/s, we selected three patients with the 
diagnosis of Zimmermann-Laband syndrome and performed a WES approach on the three patients 
and their parents in two cases. DNA variants were analyzed and prioritized based on segregation, 
sharing among patients, effect on protein structure/function and gene function. This analysis let us 
to identify two excellent candidate genes, KCNH1 and ATP6V1B2. An enlargement of the cohort 
was performed through the recruitment of further five patients in a collaborative effort with several 
international research groups. Patients were analyzed by WES or Sanger sequencing of the coding 
portion of KCNH1 and ATP6V1B2 genes confirming the presence of additional mutations.  
Overall, this analysis led to the identification of six mutations in KCNH1 gene in six 
patients, and one mutation in ATP6V1B2 gene in two patients (tables 14 and 15). All variants were 
single-nucleotide substitutions causing missense mutations, with a germline origin, and not 
annotated in any population database.  
 KCNH1 and ATP6V1B2 genes mutations were studied using in silico and functional 
approaches. 3D modeling of KCNH1 and ATP6V1B2 suggest a deleterious effect for the identified 
mutations, confirming the prediction of in silico prediction tools, as Polyphen, SIFT and CADD 
score. Electrophysiological studies of KCNH1 mutants show that all mutant channels activate to 
more negative potentials, showing a potential gain-of-function effect. 
A following enlargement of the cohort was performed with additional four patients that were 
analyzed through Sanger sequencing of the coding portion of KCNH1 and ATP6V1B2 genes, this 
screening resulted negative. Two patients were selected for WES leading to the identification of a 
potentially pathogenic mutation in one patient in the ATP6V1C1 gene, encoding an interactor of 
ATP6V1B2. 
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Common clinical features of patients mutated in KCNH1, ATP6V1B2 and ATP6V1C1 genes 
include craniofacial dysmorphism, gingival enlargement, mild to severe intellectual disability, and 
aplastic or hypoplastic nails and terminal phalanges, although with remarkable variability. Epilepsy 
was present in all six subjects with KCNH1 mutations and absent in the patients with ATP6V1B2 or 
ATP6V1C1 mutations. The face is coarser and the hypoplasia of nails and distal phalanges is more 
severe in patients with mutations in ATP6V1B2 and ATP6V1C1. Other clinical features, such as 
hearing loss and hypertrichosis, were variably present (table 15). 
 
4.1 KCNH1 
KCNH1 gene encodes a member of the potassium channel, voltage-gated, subfamily H 
protein (also called Kv10.1). KCNH1 is expressed in myoblast at the onset of fusion (Occhiodoro et 
al., 1998) and in adult brain tissue. KCNH1 protein is encoded by two different annotated 
transcripts (NM_002238, and NM_172362) which differ in the presence of 27 amino acids (aa 318–
344) between the transmembrane helices 3 and 4 and encoding the same domains: the amino-
terminal region, containing an eag (ether à go-go) domain, the carboxy-terminal region, containing 
a cyclic nucleotide binding homology domain (CNBHD), and 6 transmembrane helices (S1-S6). 
The S4 helix works as a voltage sensor domain, the S5 and S6 helices are connected by the P-loop 
and together constitute the pore. Both the N- and the C-terminal domains are cytoplasmic and are 
necessary for the gating of the channel (Haitin et al., 2013) (figure 21). 
 
 
 
Figure 21. Structure of the eag domain–CNBHD complex of mEAG1 (murine Kcnh1). Cartoon of a cross section of a 
KCNH channel. Transmembrane domains are in grey, the N-terminal eag domains are in green, the C-linkers are in 
orange and the CNBHD domains are in blue. The intrinsic ligand motifs are highlighted in yellow, and the post-
CNBHD in red (Haitin et al., 2013). 
 
The functional channel is a homo- or heterotetramer. During KCNH1 sequencing analysis 
we found an alternative isoform expressed in fibroblasts and confirmed also in fetal and adult 
human brain. This isoform lacks exon 6, encoding the first three transmembrane alpha-helices. A 
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recent study, demonstrated the presence of short splice variants of KCNH1 resulting from different 
exon-skipping events in human brain and cancer cell lines (Ramos Gomes et al., 2015). Those 
isoforms lacked the transmembrane domains of the channel and produced cytoplasmic proteins 
without channel function, that exert their functions inducing a reduction in the overall expression of 
full-length KCNH1 or affecting its glycosylation pattern. One of these isoforms triggered the 
activation of cyclin-dependent kinases in Xenopus laevis oocytes, suggesting a role in cell cycle 
control (Ramos Gomes et al., 2015). These results highlight the relevance of non-canonical 
functions of the ion channel KCNH1, whose perturbation could underlie developmental processes. 
 Gene expression and biochemical studies are ongoing to better characterize this isoform in 
terms of expression, localization and function, both in patients and in wild-type cells. 
Overall, we found 6 de novo missense variants in KCNH1 in six patients c.1054C>G, 
p.L352V; c.1405G>A, p.G469R; c.1399A>G, p.I467V; c.[974C>A;1066G>C], p.[S325Y;V356L]; 
and c.1042G>A, p.G348R through exome sequencing and Sanger sequencing screening. Mutation 
c.1399A>G, p.I467V was found in two patients (cases 4 and 7) (table 14, figure 11). 
Most mutations (p.L352V, p.G469R, p.I467V, p. V356L, and p.G348R), involve the helices 
forming pore (S5 and S6), and S325Y maps into the voltage-sensor helix (S4) (figure 11), 
suggesting that the ion conductance perturbation could underlie the pathogenic mechanism. 
3D modeling studies were performed on 4 of the 6 variants in KCNH1 (p.L352V, p.V356L, 
p.I467V, p.G469R). Mutations affecting the residues L352, V356 and I467 impair the closed/open 
transition of the channel, while the change p.G469R affects the flow of the ions through the pore 
(figure 12).These results suggest that the molecular size and charge changes of the channel pore 
could affect the proper functioning of the gate. 
Patch-clamp experiments on CHO cells expressing wild-type or mutant KCNH1 channels 
demonstrated that p.G348R, p.L352V, p.I467V and p.[S325Y; V356L] substitutions have a gain-of-
function effect, while the G469R mutant failed to produce voltage-dependent outward currents 
suggesting that the G469 residue is essential for proper channel gating (figure 13). Experiments in 
Xenopus laevis oocytes documented a dominant action of the G469R mutant over the wild-type 
channel, with reduced K+ conductance of the heterotetrameric channels at depolarizing potentials 
but with pronounced conductance at negative potentials, similar to the other ZLS-causing KCNH1 
mutants. Together, these data show a gain-of-function effect for all disease-associated KCNH1 
mutants.  
In humans, KCNH channels contribute to neuronal signaling in the nervous system and are 
important regulators of cellular excitability. They have been associated with cancer (Pardo et al., 
1999), cardiac long QT syndrome type, epilepsy and schizophrenia (Haitin et al., 2013). KCNH1 
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can also be involved in adipogenic and osteogenic differentiation in bone marrow-derived 
mesenchymal stem cells (Zhang et al., 2014). Overexpression of the gene may confer a growth 
advantage to cancer cells and favor tumor cell proliferation (Ouadid-Ahidouch et al., 2016). 
 KCNH1 plays an active role in cell cycle progression in both cancer and non-transformed 
cells. Its transcription is directly regulated by the pRb/E2F1 pathway during G2/M, resulting in 
transient expression that contributes to progression through G2/M. In HeLa cells, KCNH1 depletion 
leads to delayed G2/M progression, indicating that channel expression at the end of the cell cycle 
facilitates G2/M completion (Urrego et al., 2016) 
As recently reported, KCNH1 is a regulator of ciliogenesis (Sánchez et al., 2016). The 
cilium is used as an antennae by the cells to sense the surrounding environment and can be found in 
cells that are not actively proliferating (Sánchez et al., 2016). Experimental evidences demonstrated 
that KCNH1 localizes to the centrosome and the primary cilium and promotes ciliary disassembly.  
 This shed light on the role of KCNH1 in the modulation of ciliogenesis, and could 
potentially explain the influence of KCNH1 expression on the proliferation of normal cells and its 
tumorigenic effects. Interestingly, a mutant form of KCNH1 was studied, corresponding to mutation 
L352V found in our case 1 (Sanchez et al., 2016). The mutant form of the channel was transfected 
into wild-type mouse embryonic fibroblasts (MEFs) and its effect on ciliary resorption was tested, 
demonstrating a significant reduction of ciliated cells (Sanchez et al., 2016).  
As mutations in KCNH1 show hyperactive effects, this may disrupt cell proliferation and 
neuronal activity. It could be hypothesized that if KCNH1 is implicated in ciliary resorption, a 
developmental phenotype in the presence of channel hyperactivity could be related to impaired 
ciliogenesis.  
Interestingly, while mouse model lacking functional Kcnh1 channels appeared normal in 
their development and in brain morphology, although with mild hyperactivity (Ufartes et al., 2013), 
a recently knockdown model of Kcnh1 in zebrafish delays neural development and causes 
embryonic lethality, suggesting that Kcnh1 is involved in cell proliferation during early 
development and that it exerts basic functions beyond neural signaling (Stengel et al., 2012). 
Recently, de novo KCNH1 mutations have been reported as disease causing in individuals 
with Temple-Baraitser syndrome (TMBTS) (Simons et al., 2015; Mégarbané et al., 2016), a rare 
developmental disorder characterized by severe mental retardation and anomalies of the hands and 
feet with absence/hypoplasia of the nails. Most patients have seizures and dysmorphic facial 
features (Jacquinet et al., 2010). All nine reported TMBTS-affected individuals presented with 
absent or hypoplastic thumb and great toenails, and epileptic seizures with varying age of onset, but 
none of them was described to have gingival hyperplasia (Simons et al., 2015; Mégarbané et al., 
 2016). Functional studies in two different cell systems
KCNH1 mutations were gain-of-function mutations, lowering the activation threshold of the mutant 
KCNH1 channels and delaying their deactivation (Simons 
overlaps with ZLS in terms of orofacial and digital abnormalities
More recently, further patients with 
disability (Bramswig et al., 2015), and a phenotype characterized by 
delay, hypotonia and seizures (Fukai 
So far a total of 21 individuals with pathogenic 
(Kortum et al., 2015; Simons et al
al., 2016). These patients carry 12
hot spots corresponding to the S4
domains in KCNH1 (figure 22).
location of the affected residues and the clinical diagnosis.
 
 
Figure 22. Schematic representation of all the mutations found in 
in orange mutations reported in Simons 
mutations reported in Fukai et al., 2016, and in blue the mutation reported in Mégarbané 
 
Moreover, in at least five cases, the same mutation has been reported 
different clinical diagnosis (c.1399A>F, p.I467V associated with ZLS and TMBTS, 
2015; Simons et al., 2015). Patients share some 
face, and hypoplastic nails and termi
features, e.g. with regard to their 
and hirsutism (table 19).  
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Thus, there might be other factors involved, i.e. genetic modifiers, that prevent the 
prediction of some features, e.g. occurrence and age of onset of epileptic seizures, from the 
presence and the location of a pathogenic KCNH1 mutation. 
 
Mutation c.1399A>G p.I467V 
Reference Present work (Kortum et al., 2015) 
Simons et al., 
2015 Total 
Case 4 7 3 5 6 5 
Diagnosis ZLS TMBTS  
Sex F F M F F 1M:4F 
ID + + + NR + 4/4 
Seizures + + + + + 5/5 
Hypotonia + - + + + 4/5 
Deafness - + - - - 1/5 
Coarse 
Face + + + + + 5/5 
Gingival 
hyperplasia + - - - - 1/5 
Hypoplastic 
Nails + + + + + 5/5 
Hypoplastic 
phalanges + + + + + 5/5 
Scoliosis + NR NR NR NR 1/1 
Hirsutism + - - - - 1/5 
 
Table 19. Clinical features of the patients carrying the same mutation in KCNH1 reported in literature. 
M = male, F = female, + = present, - = absent, ID = Intellectual disability, NR = not reported, ZLS = Zimmermann-
Laband syndrome, TMBTS = Temple-Baraitser syndrome. 
 
A comparison of clinical features of all KCNH1 mutated patients to date reported in 
literature, allowed us to disclose the presence of some features shared among patients, like severe 
intellectual disability, neonatal hypotonia, seizures of varying age of onset, and hypoplastic nails.  
Even though gingival hyperplasia has not been reported in TMBTS-affected individuals 
(Simons et al. 2015), is a frequent clinical feature in individuals with KCNH1 mutations. The limb 
phenotype is variable and may include the absence/hypoplasia of the thumb nails, hallux nails, and 
other finger-/toenails. In addition, the thumbs can be long and proximally implanted. Deafness and 
hirsutism are observed in only a small fraction of the cases. The main clinical features of the 
KCNH1 mutated patients are summarized in table 20. 
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Present 
Work, 
Kortum et al., 
2015 
Simons et al., 
2015 
Bramswig et al., 
2015 
Fukai et al., 
2016 
Mégarbané et al., 
2016 Total 
N. of cases 6 6 4 4 1 21 
Diagnosis ZLS TMBTS ID SDDHS TMBTS  
Sex 2M:4F 2M:4F 4F 4M M 9M:12F 
ID 6/6 5/5 4/4 4/4 + 20/20 
Seizures 6/6 6/6 3/4 4/4 - 19/21 
Hypotonia 4/6 6/6 4/4 3/4 + 18/21 
Deafness 1/4 0/6 0/4 0/4 - 1/19 
Coarse 
Face 6/6 6/6 4/4 3/4 + 20/21 
Gingival 
hyperplasia 5/6 0/6 4/4 1/4 + 11/21 
Hypoplastic 
Nails 5/6 6/6 4/4 3/4 + 19/21 
Hypoplastic 
phalanges 4/5 5/6 0/4 0/4 - 9/20 
Scoliosis 5/6 NR NR 0/4 NR 5/10 
Hirsutism 3/6 0/6 0/4 0/4 - 3/21 
 
Table 20. A summary of the main ZLS features is presented and compared with clinical features of other KCNH1 
mutated patients. M=male, F=female, +=present, -=absent, ID=Intellectual disability, NR=not reported, 
ZLS=Zimmermann-Laband syndrome, TMBTS=Temple-Baraitser syndrome, SDDHS=Syndromic Developmental 
Delay, Hypotonia and Seizures. 
 
Therefore, we can conclude that there is not a clear genotype-phenotype correlation among 
KCNH1 mutations and clinical features and that the mutations in KCNH1 likely cause a phenotypic 
continuum of neurodevelopmental disorders covering both ZLS and TMBTS. 
More information of KCNH1 mutations and their clinical consequences are needed, in order 
to more clearly delineate the genotype-phenotype correlation, and to characterize the molecular 
mechanisms involved in the pathogenesis of this phenotypic spectrum. 
In one patient (case 5) we found two de novo mutations in KCNH1 on the same allele 
(c.[974C>A;1066G>C]; p.[S325Y;V356L]), 92 nucleotides apart (figure 9). This is a very unusual 
occurrence. Multiple mutations that exhibit nonrandom proximal spacing in higher eukaryotes are 
termed ‘‘closely spaced multiple mutations’’ (CSMMs) and are most compatible with a model in 
which they are generated simultaneously or quasi-simultaneously in the same cell cycle (Colgin et 
al., 2002; Hill et al., 2004). Examples of pathogenic CSMMs are known from a collection of human 
inherited disease-causing multiple mutations (Chen et al., 2009). Two single-base substitutions 
(C>G and T>C) separated by 25 bp, causing two different cis amino acid substitutions in the 
androgen receptor gene on the maternal X-chromosome have been reported in feminized, male 
monozygotic twins (Mongan et al., 2002). A patient with Multiple Endocrine Neoplasia, type IIA 
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(MEN2A) have been reported to have two cis missense substitutions in the RET gene resulting from 
single base substitutions (C>T and C>G) separated by 19 bp (Tessitore et al., 1999). An additional 
case with two single-base changes separated by nine nucleotides in the ELA2 gene, predicting two 
amino acid substitutions (p.V69L and p.V72L), is reported (Salipante et al., 2007). 
Multiple synchronous mutations have been postulated to arise via transient hypermutability, 
resulting from the deregulated expression of a replicative DNA polymerase or another protein 
involved in the maintenance of replication fidelity, the disruption of the balance of the nucleotide 
pool, or the recruitment of error-prone polymerases (Chen et al., 2009). The onset of CSMMs has 
been studied in mouse models or in human cell lines, but the actual mechanisms that cause them is 
not yet clear. 
One of the two changes, p.S325Y, is predicted as “pathogenic” by Polyphen, SIFT and 
CADD score, while the other, p.V356L, is predicted as “benign” by Polyphen and SIFT. Moreover, 
they map in residues that are both less conserved than the other KCNH1 mutated residues (figure 
10).  
 
4.2 ATP6V1B2 
ATP6V1B2 encodes one of two V1 domain B subunit isoforms of the V-ATPase proton 
pump and is the only B isoform highly expressed in osteoclasts. V-ATPase dependent organelle 
acidification is necessary for intracellular processes such as protein sorting, zymogen activation, 
receptor-mediated endocytosis, and synaptic vesicle proton gradient generation. V-ATPase is 
composed of a cytosolic V1 domain and a transmembrane V0 domain. The V1 domain consists of 
three A, three B, and two G subunits, as well as a C, D, E, F, and H subunit. The V1 domain 
contains the ATP catalytic site. 
We found one de novo variant in ATP6V1B2 in two ZLS patients, c.1454G>C (p.R485P), 
through exome sequencing. 3D modeling studies predicted that the substitution of the R485 with a 
proline perturb intersubunit interactions within the V1 subcomplex, possibly preventing the 
formation of a functional V-ATPase. Clinical features of cases 2 and 8 include gingival 
enlargement, anonychia of the hands and feet, aplastic terminal phalanges of the fingers and toes, 
and hypertrichosis (table 21). 
Recently, a heterozygous truncating ATP6V1B2 mutation, c.1516C>T (p.R506*), has been 
reported in three patients with autosomanl dominant deafness and onychoystrophy syndrome 
(DDOD) (Yuan et al., 2014). DDOD patients mutated in ATP6V1B2 show hypoplasia of nails and 
terminal phalanges but no intellectual disability, coarse face, gingival hyperplasia, or hirsutism 
(figure 23 and table 21). Among all the ATP6V1B2 mutated patients, deafness is present in all the 
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three DDOD cases but only in one patient analyzed in the present work (table 21). The DDOD 
mutation inserts a premature stop codon that prevents the synthesis of the last six amino acids. Cell 
studies demonstrated that the truncated protein reduced the ATP hydrolysis mediated by the V-
ATPase and also the acidification of the intracellular organelles. In figure 24 the positions of the 
mutated residues with respect to the assembled V-ATPase are represented. 
Consistent with partial clinical overlap, the ZLS- and DDOD-causing mutations in 
ATP6V1B2 affect the same protein region, which participates in V1 subcomplex assembly. These 
mutations can both lead to a reduction of the number of functional V-ATPases. Functional studies 
are required to understand the consequences of these alterations on the proper assembly/function of 
the V-ATPase. 
 
 
 
Figure 23. (A-C, F-H) Hands and feet of three patients with DDOD, mutated in ATP6V1B2 (Yuan et al., 2014), 
(D,E,I,J) Hands and feet of cases 7 and 8 of the present work, mutated in ATP6V1B2 (Kortum et al., 2015). (A-C) 
Pictures of the hands of the DDOD patients showing the absence of the fifth finger and thumb nails indicated by black 
arrows, aplasia of the middle phalanx in the fifth fingers indicated by white arrows, hypoplasia of the middle three 
fingernails. (F-G) Pictures of the feet of the DDOD patients showing the absence of all toenails. (D,E,I,J) Hands and 
feet of cases 7 and 8 with ZLS showing nails and phalanges aplasia. (D,I) Case 7 shows shortened second to fourth 
fingers, except the third finger on the right hand, and toes. Case 8 shows aplastic terminal phalanges of the fifth finger 
on the right hand and all toes except the first. 
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Mutation c.1454G>C p.R485P 
c.1516C>T 
p.R506* 
Reference Present work (Kortum et al., 2015) 
Yuan et al., 
2014 
Case 2 8 1 2 3 
Diagnosis ZLS DDOD 
Sex F M F M F 
ID + + - - - 
Seizures - - - - - 
Hypotonia + + - - - 
Deafness - + + + + 
Coarse 
face + + - - - 
Gingival 
hyperplasia + + - - - 
Hypoplastic 
nails + + + + + 
Hypoplastic 
phalanges + + + + + 
Scoliosis - + NR NR NR 
Hirsutism + + - - - 
 
Table 21. A summary of the main clinical feature of ATP6V1B2 mutated patients. 
M = male, F = female, + = present, - = absent, NR = not reported, ZLS = Zimmermann-Laband syndrome, DDOD = 
Dominant deafness onychodystrophy syndrome. 
 
 
 
Figure 24. Schematic view of the subunit structure of the V-ATPase. The catalytic V1 complex consists of the A, B, C, 
D, E, F, G and H subunits. The V0 domain is membrane embedded and is composed of a characteristic C-ring structure 
with which the a, d and e subunits are associated. The blue dot indicate the R485 residue, the green dot represent the 
R506 residue.  
 
4.3 ATP6V1C1 
ATP6V1C1 encodes the subunit C, that constitutes the V1 subcomplex of the V-ATPase 
proton pump. The subunit C, together with the subunits E, G, and H, and the N-terminal domain of 
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subunit a, make up the peripheral stalks and serve to tether V1 to V0 subcomplexes (Cotter et al., 
2015). ATP6V1C1 has also a regulatory role in the V-ATPase assembly. It can trigger the 
formation of functional proton pumps in response to various stimuli, like increasing of glucose 
level, activation of PI3K, mTORC1 and EGF pathways (Cotter et al., 2015). 
ATP6V1C1 is expressed in activated osteoclasts when these cells operate bone reabsorption 
(Feng et al., 2009). ATP6V1C1 can also bind G-actin, increasing its polymerization rate, 
stabilization and crosslinking F-actin (Vitavska et al., 2003, Vitavaska et al., 2005). Another 
important function is its role in cellular proliferation, it is indeed overexpressed in several type of 
cancers like oral squamous carcinoma and breast cancer (Feng et al., 2014). 
By WES approach we found a de novo mutation in ATP6V1C1, c.865G>A (p.E289K) in one 
ZLS patient. This patient (case 9) shows remarkably overlapping features with ATP6V1B2 mutated 
patients analyzed in the present work. Those patients share a coarse face, intellectual disability, and 
hypoplastic nails and phalanges, although ATP6V1C1 mutated individual lacks gingival hyperplasia 
and hirsutism (table 22). 
ATP6V1B2 and ATP6V1C1 constitute the V1 subcomplex, ATP6V1B2-econded subunit 
constitutes the ATPase domain together with the A subunits, while the C subunit constitutes the 
stalk that link A-B subunits to the Vo subcomplex. On the basis of the phenotypic similarity among 
ATP6V1B2- and ATP6V1C1-mutated patients and the structural analysis of ATP6V1B2 mutant 
protein, it can be hypothesized that the p.E289K mutation of ATP6V1C1 could exert a similar 
effect, impairing the biogenesis of a functional V-ATPase. Structural and functional studies are 
ongoing to characterize the effect of the p.E289K mutation on the proper assembly/activity of the 
ATPase complex. 
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Gene ATP6V1B2 ATP6V1C1 
Mutation c.1454G>C p.R485P 
c.865G>A 
p.E289K 
Case 2 8 9 
Sex F M F 
ID + + + 
Seizures - - - 
Deafness - + + 
Coarse 
face + + + 
Gingival 
hyperplasia + + - 
Hypoplastic 
nails + + + 
Hypoplastic 
phalanges + + + 
Scoliosis - + NR 
Hirsutism + + - 
 
Table 22. A comparison of the main clinical features of patients ATP6V1B2 and ATP6V1C1 mutated respectively. 
M=male, F=female, +=present, -=absent, NR=not reported. 
 
The mosaicism for the ATP6V1C1 variant allele in the father’s proband fitted with a mild 
manifestation of some ZLS features also in this subject.  
Standard workflow analyses of WES data were not able to detect the presence of the 
pathogenic allele in the father’s blood cells, as the algorithm used to disclose the presence of DNA 
mutations discards reads in low percentage, as they potentially represent sequencing and/or 
alignment errors. When a different pipeline (MuTect2, Cibulskis et al., 2013), specifically designed 
to disclose the presence of low percentage variant allele, was used, we were able to identify the 
mutation also in the mildly affected father (figures 16 and 19). This suggests that using 
bioinformatic tools that usually identify somatic mutations in tumoral samples, can be useful also 
for Mendelian diseases. 
These results confirmed the role of mosaicism in Mendelian diseases, causing a milder 
phenotype than when present in the germline. Recent technological advances in genomics have 
enhanced the ability to detect and characterize different types of mosaicism with increasing 
sensitivity, demonstrating the widespread nature of mosaicism in a wide range of disorders. 
 Although the accurate differentiation between sequencing error and a mosaic mutation is a 
challenging task, mosaicism levels as low as 2% could be distinguished from sequencing errors 
using dedicated analysis tools. Mosaic disorders pose a new challenge for genotype-phenotype 
correlations and prediction of disease manifestations and severity, with several clinical implications, 
in terms of recurrence risk and prognosis. 
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4.4 ATP6V1B2 and ATP6V1C1: the role of V-ATPase 
The eukaryotic V-type ATPase (V-ATPase) is a multi-subunit membrane protein complex 
that has an important role in both endocytosis and intracellular transport. In receptor-mediated 
endocytosis, a low pH within early endosomes triggers the dissociation of internalized ligand–
receptor complexes. This allows for recycling of receptors to the plasma membrane, V-ATPases 
located in the apical membrane of type-A renal intercalated cells function in proton secretion into 
the renal fluid and hence in acid–base balance in the kidney, in macrophages and neutrophils.
 Plasma membrane V-ATPases also have an important role in bone resorption. Osteoclasts 
attach to the surface of bone to create a sealed extracellular compartment, acidification of this space 
serves to both dissolve the bone matrix and to increase the activity of acid hydrolases that are 
secreted by the osteoclast (Nishi and Forgac, 2002). 
Several pathways have been identified (e.g. mTOR pathway, WNT signal transduction 
pathway, Notch pathway) involving V-ATPase functions (Sun-Wada and Wada 2015), highlighting 
its crucial role in cell pathways whose dysregulation could underlie ZLS pathogenesis. To date, 
there are no clear links between V-ATPase cell functions and pathogenic mechanisms underlying 
ZLS phenotype. The identification of a further mutated subunit in a ZLS patient and the clinical 
overlap of ATP6V1B2 and ATP6V1C1 mutated patients suggests that V-ATPase have a significant 
role in developmental processes, yet to be identified, whose dysregulation could determine several 
developmental defects.  
 
4.5 Mutations in ATP6V1B2, ATP6V1C1, and KCNH1: the question of 
splitting or lumping 
We identified KCNH1, ATP6V1B2, and ATP6V1C1 as disease-associated genes for ZLS. So 
far, only hypothetical functional links exist between KCNH1, and ATP6V1B2 and ATP6V1C1. Both 
the V-ATPase and KCNH1 have been shown to regulate neurotransmitter release and are important 
for synaptic transmission (Mortensen et al., 2014; Poëa-Guyon et al., 2013). The V-ATPase, as 
already stated, serves in the acidification of intracellular organelles, and effective proton pumping 
requires the movement of a counterion. Initial data indicate that K+ could act as the counterion 
(Steinberg et al., 2010). Rapid internalization of plasma membrane–localized KCNH1 and its 
sorting to lysosomes provide a first clue of the function of KCNH1 in lysosomal conductive 
pathways. Alternatively, altered acidification of intracellular compartments may lead to 
disturbances in cellular transport processes in general and to perturbed regulation of KCNH1 
trafficking in particular (Kohl et al., 2011). 
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A comparison of phenotypes associated with mutations in KCNH1 and ATPase subunits 
suggests that ATPase subunits mutations cause a more pronounced phenotype characterized mostly 
by hypertrichosis, limb anomalies (including aplastic terminal phalanges and anonychia of hands 
and feet), and a coarser facial phenotype. These results suggest that there is a clinical overlap but 
probably they represent distinct phenotypes.  
The original and following published patients with a clinical diagnosis of ZLS also show 
coarse facial features, a large nose which can be poorly formed due to soft cartilage and hypoplastic 
terminal phalanges (Bazopoulou-Kyrkanidou et al. 1990; Laband et al. 1964). Taken together, all 
these results led us to hypothesize that the ZLS patients with KCNH1 mutations belong to the 
TMBTS spectrum, while the individuals with ATP6V1B2 and ATP6V1C1 mutations represent the 
original and more severe ZLS spectrum. This led to a debate, about the “splitting” or “lumping” 
approach to study these disorders (Bramswig et al., 2015), that is still ongoing. 
However, due to the limited number of individuals described, some with only scarce clinical 
data and no clinical photographs, it is difficult to draw an accurate conclusion. Additional patients 
with a TMBTS/ZLS phenotype are needed to further investigate this phenotypic spectrum and give 
some hints to come to a final conclusion about the above-mentioned hypotheses. It would be 
insightful also to perform a detailed characterization of the molecular bases of these disorders, in 
order to understand the mechanisms by which these genes cause the pathogenesis of these 
syndromes. 
Moreover, the presence of several ZLS patients (Kortum et al., 2015 and the present work) 
mutation negative for KCNH1, ATP6V1B2, and ATP6V1C1 suggests further genetic heterogeneity. 
To this aim, we are currently recruiting patients with ZLS and ZLS-like phenotype. Patients 
will be screened by Sanger sequencing of the coding portions of KCNH1, ATP6V1B2, ATP6V1C1 
genes. Mutation positive patients will be analyzed in order to provide a more accurate picture of the 
molecular spectrum of mutations and their associated clinical spectrum. Patients that will be found 
mutation negative will be considered for WES/WGS-based approaches directed to identify the 
missing disease genes. 
Functional studies are ongoing in order to better characterize the altered function of the 
mutated genes and the perturbed pathways that cause the pathogenic mechanism. 
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5. Conclusions 
Zimmermann-Laband syndrome is a rare developmental disorder characterized by facial 
dysmorphism, nail aplasia or hypoplasia, hypertrichosis, and intellectual disability with or without 
epilepsy. In this work (Kortum et al., 2015) we identified for the first time the causative genes that 
highlight the role of potassium channels (KCNH1) and the vacuolar ATPase (ATP6V1B2 and 
ATP6V1C1) in the pathogenesis of this disorder. 
The identification of two genes (KCNH1 and ATP6V1B2) involved also in clinically 
overlapping phenotypes (Temple-Baraitser syndrome, intellectual disability, syndromic 
developmental delay, hypotonia and seizures and dominant deafness and onychodystrophy 
syndrome), suggest that they cause a phenotypic spectrum. These observations allowed to conclude 
that the characterization of the molecular bases of these overlapping syndromes could represents a 
powerful tool for their classification. 
Genetic evidence points to a genetically heterogeneity for ZLS, indicating that additional 
unknown genes are involved. An enlargement of the cohort of patients would provide additional 
data to perform genotype-phenotype correlations and further characterize the genetic heterogeneity 
of this syndrome. 
Our understanding of the molecular events underlying this condition will provide new tools 
for diagnosis of this rare disorder, with direct impact on diagnosis, prognosis, counseling, and 
patient management. 
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